azacitidine has been researched along with cytarabine in 264 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 89 (33.71) | 18.7374 |
| 1990's | 33 (12.50) | 18.2507 |
| 2000's | 12 (4.55) | 29.6817 |
| 2010's | 96 (36.36) | 24.3611 |
| 2020's | 34 (12.88) | 2.80 |
| Authors | Studies |
|---|---|
| Abbasi, MM; Beisler, JA; Driscoll, JS | 2 |
| Hansch, C; Khwaja, TA; Selassie, CD | 1 |
| Cook, PD; McNamara, DJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Borsos, T; Ohanian, SH; Segerling, M | 2 |
| Chabner, BA; Coleman, CN; Johns, DG; Myers, CE | 1 |
| Karon, M; Lee, T; Monparler, RL | 1 |
| Comelli, A; Massimo, L | 1 |
| Anderson, JE; Giblett, ER; Teng, YS | 1 |
| Goodman, J; Karon, M; Momparler, RL | 1 |
| Chabner, BA; Coleman, CN; Drake, JC; Stoller, RG | 1 |
| Cihak, A | 1 |
| Bloch, A | 1 |
| Wentworth, DF; Wolfenden, R | 1 |
| Chabner, BA; Chang, P; Coleman, CN; Hande, KR; Stoller, RG | 1 |
| Benedict, WF; Khwaja, TA | 1 |
| Wiernik, PH | 1 |
| Bear, RA; Garvey, MB; Ho, M | 1 |
| Ng, SK; Rogers, J; Sanwal, BD | 1 |
| Chabner, BA; Myers, CE; Oliverio, VT | 1 |
| Preisler, HD; Renick, J; Rustum, YM; Walczak, I | 1 |
| Bender, RA; Chabner, BA; Cohen, M; Doroshow, JH; Hande, KR; Locker, GY; Murinson, DS; Myers, CE; Zwelling, LA | 1 |
| Cassileth, PA; Cooper, RA; Katz, ME; Petrillo, MH | 1 |
| Belt, J; Brenner, MK; Crom, W; Hurwitz, CA; Krance, R; Mahmoud, H; Ribeirio, R; Roberts, WM; Santana, VM; Schell, MJ | 1 |
| Camitta, BP; Clavell, LA; Gelber, RD; Grier, HE; Link, MP; Weistein, HJ | 1 |
| Laliberté, J; Marquez, VE; Momparler, RL | 1 |
| Abella, E; Alvarado, CS; Chauvenet, A; Dubowy, R; Harris, M; Inoue, S; Krischer, JP; Ravindranath, Y; Ritchey, AK; Wiley, J | 1 |
| McCulloch, EA; Yang, GS | 1 |
| Buckley, JD; Hammond, GD; Lampkin, BC; Woods, WG | 1 |
| Gray, RG; Rees, JK | 1 |
| Fiere, D; Haanen, C; Jehn, U; Löwenberg, B; Peetermans, M; Solbu, G; Stryckmans, P; Suciu, S; Willemze, R; Zittoun, R | 1 |
| Heinemann, V; Jehn, U | 1 |
| Champlin, R; Gajewski, J; Ho, W; Landaw, E; Nimer, S; Schiller, G; Vollset, S; Winston, D | 1 |
| Allegra, CJ; Grem, JL | 2 |
| Momparler, LF; Momparler, RL; Onetto-Pothier, N | 1 |
| Ho, T; Holliday, R | 1 |
| Chou, TC; Kong, XB; Tong, WP | 1 |
| Gellersen, B; Kempf, R | 1 |
| Galanello, R; Papayannopoulou, T; Stamatoyannopoulos, G; Veith, R | 1 |
| Dean, A; Fordis, CM; Ley, T; Schechter, AN; Wu, YJ | 1 |
| Bigner, DD; Friedman, HS; Schold, SC | 1 |
| Platt, OS | 1 |
| Boyett, J; Kitchens, CS; Kramer, BS; Noyes, WD; Oblon, DJ; Ross, W; Weiner, RS | 1 |
| Lampkin, BC | 1 |
| Driscoll, JS; Johns, DG; Plowman, J | 1 |
| DeSimone, J; Hall, L; Heller, P; Lavelle, D; Zwiers, D | 1 |
| Pískala, A; Veselý, J | 1 |
| Moriconi, WJ; Slavik, M; Taylor, S | 1 |
| Kissinger, LD; Stemm, NL | 1 |
| Holliday, R | 1 |
| Estey, E; Silberman, L; Zwelling, LA | 1 |
| Bhalla, K; Gleyzer, M; Grant, S | 1 |
| Csordas, A; Schauenstein, K | 1 |
| Dahl, GV; Jackson, CW; Kalwinsky, DK; Look, AT; Mirro, J | 1 |
| Colombo, T; D'Incalci, M; Rossi, C | 1 |
| McCulloch, EA; Wang, C | 1 |
| Borri-Voltattorni, C; Dominici, P; Fioretti, MC; Fuschiotti, P; Puccetti, P; Romani, L | 1 |
| Burnison, M; Champlin, R; Decker, R; Gale, RP; Greenberg, P; Ho, W; Holly, FE; Winston, D | 1 |
| Gyger, M; Momparler, LF; Momparler, RL; Onetto, N | 1 |
| Antonsson, BE; Avramis, VI; Holcenberg, JS; Nyce, J | 1 |
| Catovsky, D; Chessells, JM; Galton, DA; Goldman, JM; Hann, IM; Hoffbrand, AV; Marcus, RE; Newland, AC; Prentice, HG; Stevens, RF | 1 |
| Gray, R; Hayhoe, FG; Rees, JK | 1 |
| Jones, PA; Michalowsky, LA | 1 |
| Chan, HS; Estrov, Z; Freedman, MH; Weitzman, SS | 1 |
| Csordas, A; Rossi, K; Schauenstein, K | 1 |
| Galanello, R; Papayannopoulou, T; Stamatoyannopoulos, G | 1 |
| Pfeifer, GP; Steigerwald, SD | 1 |
| Colly, LP; Lurvink, E; Richel, DJ; Willemze, R | 1 |
| Baehner, RL; Buckley, JD; Chard, RL; Hammond, GD; Lampkin, BC; Nesbit, ME; Woods, WG | 1 |
| De Giovanni, C; Del Re, B; Landuzzi, L; Lollini, PL; Nanni, P; Nicoletti, G; Prodi, G; Scotlandi, K | 1 |
| Avramis, VI; Holcenberg, JS; Mecum, RA; Nyce, J; Steele, DA | 1 |
| Barbieri, R; Biancha Scarrà, G; Fiorentini, P; Gambari, R; Garrè, C; Nastruzzi, C; Ravazzolo, R; Sessarego, M | 1 |
| Constantoulakis, P; Knitter, G; Stamatoyannopoulos, G | 1 |
| Momparler, LF; Momparler, RL | 1 |
| Durr, FE; Lindh, D; Wallace, RE | 1 |
| Aiba, K; Allegra, CJ; Baram, J; Chabner, BA; Curt, GA; Yeh, GC | 1 |
| Jehn, U; Zittoun, R | 1 |
| Glynn, JP; Goldberg, AI; Goldin, A; Kende, M; Mantel, N | 1 |
| Oliverio, VT | 1 |
| Benedict, WF; Karon, M | 1 |
| Burchenal, JH; Carter, SK | 1 |
| Tobey, RA | 1 |
| Gang, M; Kline, I; Sirica, AE; Venditti, JM; Woodman, RJ | 1 |
| Chabner, BA; Drake, JC; Johns, DG | 1 |
| Cihák, A; Veselỳ, J | 1 |
| Grignani, F; Martelli, M; Tonato, M | 1 |
| Momparler, LF; Momparler, RL; Samson, J | 1 |
| Detke, S | 1 |
| Baehner, RL; Bernstein, ID; Chard, RL; Hammond, D; Higgins, G; McCreadie, S; Sather, H | 1 |
| Canivet, M; Dianoux, L; Hojman-Montes de Oca, F; Lasneret, J; Périès, J; Ravicovitch-Ravier, R | 1 |
| Lee, MH; Sartorelli, AC | 1 |
| Jones, PA; Taylor, SM | 1 |
| Coulter, DM; Presant, CA; Valeriote, F; Vietti, TJ | 1 |
| Benoit, P; Demers, J; Lin, K; Momparler, LF; Momparler, RL; Raymond, R; Rivard, GE | 1 |
| Ellims, PH | 1 |
| Bouchard, J; Chabot, GG; Momparler, RL | 1 |
| Campbell, J; Li, ZR; Rustum, YM | 1 |
| Kolata, G | 1 |
| Chabner, BA; Clendeninn, NJ; Curt, GA | 1 |
| Boccia, R; Champlin, R; Elashoff, R; Foon, K; Gale, RP; Jacobs, A; Zighelboim, J | 1 |
| Go, B; Gordon, DS; Meyer, L; Raney, MR; Vogler, WR; Winton, EF | 1 |
| Curtis, JE; McCulloch, EA; Motoji, T; Smith, LJ | 1 |
| Attadia, V; Cimino, R; Maio, M; Pinto, A; Zappacosta, S | 1 |
| Chabot, GG; Momparler, RL | 1 |
| Novotný, L; Pískala, A; Vachálková, A | 1 |
| Bøyum, A; Løvhaug, D; Nordlie, EM; Seeberg, E | 1 |
| Caspary, WJ; Hines, KC; Spencer, DL | 1 |
| Chen, YL; Wu, RT | 1 |
| Honders, WH; Landegent, JE; Ruiz van Haperen, VW; Stegmann, AP; Willemze, R | 1 |
| Jehn, U | 1 |
| Jahan, N; Mitsuya, H; O'Brien, MC; Ueno, T; Zajac-Kaye, M | 1 |
| Honders, MW; Landegent, JE; Stegmann, AP; Willemze, R | 1 |
| Hagemeijer, A; Hoebee, B; Honders, MW; Landegent, JE; Stegmann, AP; Willemze, R | 1 |
| Bartolucci, AA; Moore, JO; Omura, GA; Stagg, M; Volger, WR; Weiner, RS | 1 |
| Honders, MW; Kester, MG; Landegent, JE; Stegmann, AP; Willemze, R | 1 |
| Côté, S; Momparler, RL | 1 |
| Catapano, CV; Colombo, T; Conter, V; Damia, G; Gervasoni, M; Giudici, G; Limonta, M; Liso, V; Masera, G; Specchia, G | 1 |
| Ferrini, PR; Santini, V | 1 |
| Cournoyer, D; Eliopoulos, N; Momparler, RL | 1 |
| Beauséjour, C; Eliopoulos, N; Momparler, RL | 1 |
| Camitta, B; Carroll, AJ; Chang, M; Gresik, MV; Raimondi, SC; Ravindranath, Y; Steuber, CP; Weinstein, H | 1 |
| Beauséjour, CM; Eliopoulos, N; Le, NL; Momparler, L; Momparler, RL | 1 |
| Cunha, KS; de Andrade, HH; Graf, U; Reguly, ML | 1 |
| Beauséjour, CM; Gagnon, J; Momparler, RL; Primeau, M | 1 |
| Barge, RM; Honders, MW; Spoelder, HE; Veuger, MJ; Willemze, R | 1 |
| Broekhuizen, AJ; Creutzig, U; Gibson, BE; Hubeek, I; Kaspers, GJ; Peters, GJ; Sargent, J | 1 |
| Bouabdallah, K; Daskalakis, M; Johansson, B; Kunzmann, R; Lübbert, M; Mauritzson, N; Müller-Berndorff, H; Onida, F; Schmitt-Gräff, A | 1 |
| Aung, L; Kirk, RC; Liang, S; Quah, TC; Tan, RM; Yeoh, AE | 1 |
| Chen, R; Garcia-Manero, G; Issa, JP; Jelinek, J; Qin, T; Yang, AS; Youssef, EM | 1 |
| Craig, CM; Schiller, GJ | 1 |
| Karp, J | 1 |
| Berry, D; Borthakur, G; Faderl, S; Ferrajoli, A; Huang, X; Issa, JP; Kantarjian, H; Morris, G; Ravandi, F; Torma, R | 1 |
| Backstrom, J; Beach, CL; Beyne-Rauzy, O; Duehrsen, U; Fenaux, P; Gattermann, N; Gore, SD; Hellström-Lindberg, E; List, A; McKenzie, D; Mufti, GJ; Ramos, F; Seymour, JF | 1 |
| Rogers, BB | 1 |
| Breiling, A; Lyko, F; Musch, T; Oz, Y | 1 |
| Karaman, R | 1 |
| Czemerska, M; Grzybowska-Izydorczyk, O; Pluta, A; Robak, T; Szmigielska-Kapłon, A; Wierzbowska, A; Wolska, A | 1 |
| Bose, JR; Brenet, F; Curcio, TJ; Feldman, EJ; Gergis, US; Ippoliti, CM; Mayer, SA; Moh, M; Morawa, E; Ritchie, EK; Roboz, GJ; Scandura, JM; Villegas, L | 1 |
| Advani, A; Copelan, E; Ebrahem, Q; Gu, X; Hu, Z; Kalaycio, M; Link, KA; Maciejewski, J; Mahfouz, RZ; Mulloy, JC; Negrotto, S; Ng, KP; Radivoyevitch, T; Saunthararajah, Y; Sekeres, M; Sobecks, R | 1 |
| Bechelli, J; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Lu, C; Messina, P; Mulford, D; Phillips Ii, GL; Rosell, KE | 1 |
| Chae, YS; Kang, BW; Kim, JG; Lee, SJ; Lee, YJ; Moon, JH; Sohn, SK; Suh, JS | 1 |
| Kucerova, L; Matuskova, M; Poturnajova, M; Tyciakova, S | 1 |
| Borthakur, G; Burger, J; Faderl, S; Feliu, J; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, HM; Konopleva, M; Ravandi, F; Wang, X | 1 |
| Chang, C; He, Q; Li, X; Wu, L; Xu, F; Zhang, Y; Zhang, Z | 1 |
| Arthur, C; Buckstein, R; Cermak, J; Chou, WC; Delaunay, J; Dmoszynska, A; Faderl, S; Gau, JP; Kantarjian, HM; Kuo, CY; Lysák, D; Mayer, J; Mazur, G; Minden, M; Oriol, A; Ravandi, F; Thomas, XG; Wierzbowska, A | 1 |
| Ritchie, EK | 1 |
| Chang, CK; He, Q; Li, X; Song, LX; Wu, LY; Xu, L; Zhang, QX; Zhang, Y | 1 |
| Roboz, GJ | 1 |
| Chang, C; Fei, C; Gu, S; Guo, J; Li, X; Zhang, X; Zhang, Y; Zhao, Y | 1 |
| Agresta, S; Amrein, PC; Attar, EC; Ballen, KK; Borger, DR; Burke, M; Chen, YB; Edmonds, KM; Emadi, A; Fathi, AT; Foster, J; Hill, C; Iafrate, AJ; Lopez, HU; Matulis, CR; Neuberg, DS; Sadrzadeh, H; Schenkein, DP; Stone, RM; Straley, KS; Yen, KE | 1 |
| Ferrara, F; Musto, P | 1 |
| Bertz, H; Finke, J; Lübbert, M; Müller, MJ | 1 |
| Chan, K; Covey, J; Ebrahem, Q; Engelke, KJ; Gu, X; Jankowska, A; Ling, Y; Maciejewski, J; Mahfouz, RZ; Radivoyevitch, T; Saunthararajah, Y; Sekeres, MA; Tabarroki, A; Terse, P; Tiu, R; Visconte, V | 1 |
| Bowen, DT; Durairaj, S; Groves, MJ; Hyslop, A; Keenan, N; Tauro, S | 1 |
| Berdel, WE; Brandts, CH; Büchner, T; Bug, G; Dührsen, U; Ehninger, G; Gerss, J; Koschmieder, A; Koschmieder, S; Krug, U; Müller-Tidow, C; Noppeney, R; Röllig, C; Schaich, M; Schwammbach, D; Serve, H; Steffen, B; Stelljes, M; Thiede, C; Tidow, N | 1 |
| Atenafu, EG; Brandwein, JM; Craddock, KJ; Gupta, V; Kennedy, JA; Lipton, JH; Messner, HA; Minden, MD; Schimmer, AD; Schuh, AC; Yee, KW | 1 |
| Côté, S; Momparler, LF; Momparler, RL | 1 |
| Boddy, N; Burrows, F; Pallis, M; Russell, N; Seedhouse, C; Whittall, A | 1 |
| Adès, L; Ame, S; Beyne-Rauzy, O; Braun, T; Charbonnier, A; Delaunay, J; Dreyfus, F; Fenaux, P; Prebet, T; Raffoux, E; Stammatoullas, A; Vey, N; Wattel, E | 1 |
| Fernández-Sojo, J; Oliveras Vilà, T; Ribera, JM; Vives, S | 1 |
| Akasaka, T; Honjo, G; Izumi, K; Kishimori, C; Maesako, Y; Ohno, H; Okamori, S; Okumura, A; Takeoka, K | 1 |
| Sekeres, MA | 1 |
| Prada Garcia, C; Rodriguez Prieto, MÁ; Sanchez Sambucety, P | 1 |
| Al Ali, NH; Bello, CM; Duong, VH; Fernandez, HF; Jaglal, MV; Komrokji, RS; Lancet, JE; List, AF; Padron, E | 1 |
| Robak, T; Wierzbowska, A | 1 |
| Kearns, P; Leonard, SM; Perry, T; Woodman, CB | 1 |
| Tohyama, K | 1 |
| Arthur, C; Berrak, E; Delaunay, J; Jones, M; Kantarjian, HM; Li, Y; Mayer, J; Mazur, G; Ravandi, F; Thomas, XG; Wierzbowska, A | 1 |
| Bochtler, T; Dietrich, S; Dreger, P; Ho, AD; Krämer, A; Luft, T; Radujkovic, A; Schöning, T | 1 |
| Cabrera, JR; de Laiglesia, A; de Pablo, R; Dorado, N; Forés, R; García-Marco, JA; Lario, A; Piris, M; Regidor, C; Vilches, C | 1 |
| Desjonqueres, A; Eveillard, M | 1 |
| Benton, CB; Borthakur, G; Dara, S; Franklin, AR; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Kwari, M; O'Brien, S; Pierce, SR; Ravandi, F; Rytting, M; Thomas, DA; Yang, H | 1 |
| Jing, Y; Liu, SY; Niu, JH; Yang, H; Yu, L; Zhang, Q; Zhu, CY; Zhu, HY | 2 |
| Cui, GX; Wu, WZ; Zhang, YP | 1 |
| Chen, S; Fu, Z; Gao, S; Han, Y; Jin, Z; Ma, X; Qiu, H; Sun, A; Tang, X; Wu, D | 1 |
| Ho, A; Lao, Z; Wong, GC; Yiu, R | 1 |
| Erba, HP | 1 |
| Baczyńska, D; Butrym, A; Kuliczkowski, K; Mazur, G; Rybka, J; Tukiendorf, A | 1 |
| Chen, Y; Ding, J; Duan, L; Gu, J; Hong, M; Li, J; Li, Y; Liu, P; Lu, H; Pan, L; Qian, S; Qiu, H; Shi, J; Wang, J; Wu, H; Xu, J; Xu, Y; Yu, K; Zhang, R; Zhang, S; Zhou, J; Zhou, S; Zhu, H; Zhu, Y | 1 |
| Ford, LA; Gandhi, S; Griffiths, EA; Gupta, N; Miller, A; Thompson, JE; Vigil, CE; Wang, ES; Wetzler, M | 1 |
| Borthakur, G; Brandt, M; Burger, J; Cortes, J; Faderl, S; Feliu, J; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, TM; Kantarjian, H; Konopleva, M; Pierce, S; Ravandi, F; Wang, X | 1 |
| Berda, Y; Ciccolini, J; Costello, R; Fanciullino, R; Fina, F; Lacarelle, B; Mercier, C; Ouafik, L; Serdjebi, C | 1 |
| De Castro, CM; Griffin, PT; Komrokji, RS; Lancet, JE; List, AF; Melchert, M; Rizzieri, DA | 1 |
| Auboeuf, D; Balsat, M; Campos, L; Cheok, M; Cros, E; Dumontet, C; El-Hamri, M; Flandrin-Gresta, P; Guyotat, D; Koering, C; Michallet, M; Mohamed, AM; Mortada, H; Mortreux, F; Nibourel, O; Nicolini, F; Payen-Gay, L; Pinatel, C; Preudhomme, C; Solly, F; Thenoz, M; Thomas, X; Wattel, E | 1 |
| Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL | 1 |
| Dou, MH; Hu, C; Huang, J; Jin, J; Li, Y; Lou, YJ; Luo, YW; Ma, LY; Mao, LP; Mei, C; Niu, LM; Ren, YL; Tong, HY; Wang, JH; Wei, JY; Xie, LL; Xu, GX; Ye, L; Ye, XN; Yu, WJ; Zhou, XP | 1 |
| Tan, H; Wang, C; Xie, B; Xu, J; Yu, B; Zheng, R | 1 |
| Carter, BZ; Dai, M; Ding, B; Jiang, L; Jiang, X; Liang, S; Liu, Q; Meng, F; Wang, Z; Ye, J; Yin, C; Yu, G; Zhang, Y; Zhao, Q; Zhong, Q | 1 |
| Chang, C; Chao, X; He, Q; Li, X; Song, L; Su, J; Wu, D; Wu, L; Xu, F; Zhang, Z; Zhao, Y; Zhou, L | 1 |
| Chen, SN; Fu, JH; Gao, S; Han, Y; Hu, XH; Jin, ZM; Li, Z; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xu, Y | 1 |
| Baldus, CD; Berdel, WE; Brümmendorf, TH; Butterfaß-Bahloul, T; Dugas, M; Ehninger, G; Eveslage, M; Frickhofen, N; Gerss, J; Giagounidis, A; Görner, M; Götze, K; Hänel, M; Herr, W; Kaiser, U; Kaufmann, M; Kiani, A; Kiehl, M; Koschmieder, A; Koschmieder, S; Krause, SW; Krug, U; Kunzmann, V; Link, H; Müller-Tidow, C; Naumann, R; Neubauer, A; Noppeney, R; Peceny, R; Reichle, A; Repp, R; Röllig, C; Schäfer-Eckart, K; Schmitz, N; Serve, H; Steffen, B; Stelljes, M; Thiede, C; Thiem, U; Tschanter, P; Wagner, R | 1 |
| Becker, PS; Dean, C; Deeg, HJ; Estey, E; Hendrie, P; Mawad, R; Myint, H; Pagel, JM; Sandhu, V; Scott, B; Singer, JW; Walter, R; Wang, L; Wood, BL | 1 |
| Chen, S; Qiu, H; Shen, H; Sun, A; Sun, Y; Wu, D; Xu, Y; Yang, Z | 1 |
| Al-Kali, A; Baidoun, F; Elliott, M; Hashmi, S; Hogan, W; Hreh, M; Litzow, M; Patnaik, M; Subari, S | 1 |
| Arceci, RJ; Elmoneim, AA; Heuston, E; Triche, T; Wai, DH | 1 |
| Bainschab, A; Greinix, HT; Krause, R; Quehenberger, F; Sill, H; Wölfler, A; Zebisch, A | 1 |
| Hu, C; Jin, J; Lin, P; Lou, Y; Luo, Y; Ma, L; Mai, W; Mei, C; Meng, H; Qian, J; Qian, W; Ren, Y; Tong, H; Wei, J; Xie, L; Xu, G; Xu, W; Ye, L; Ye, X; Zhou, X | 1 |
| Chen, Y; Huang, J; Li, J; Li, Y; Lian, Y; Qian, S; Wu, Y; Xie, Y; Zhang, X; Zhao, H; Zhu, Y | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
| Bhalla, K; Boddu, PC; Cortes, JE; DiNardo, CD; Garcia-Manero, G; Jabbour, EJ; Jain, N; Kadia, TM; Kantarjian, HM; Konopleva, M; Ohanian, M; Pemmaraju, N; Pierce, S; Ravandi, F; Takahashi, K; Verstovsek, S; Wierda, WG | 1 |
| Chen, P; Dong, X; Gu, L; Li, D; Shao, J; Xu, L; Yang, Y; Zhao, H | 1 |
| Liu, P; Zhang, H; Zhou, S | 1 |
| Helleday, T; Henter, JI; Herold, N; Kutzner, J; Myrberg, IH; Olsen, TK; Paulin, CBJ; Rudd, SG; Sanjiv, K; Schaller, T | 1 |
| Becker, PS; Buckley, SA; Chen, TL; Estey, EH; Halpern, AB; Hendrie, PC; Huebner, EM; Orlowski, KF; Othus, M; Percival, MM; Pogosova-Agadjanyan, EL; Scott, BL; Stirewalt, DL; Walter, RB | 1 |
| Alvaro, F; Arceci, RJ; Arndt, C; Barnette, P; Boklan, J; Carpten, J; Cooper, T; Farrar, JE; Gooden, GC; Gore, L; Lee, D; Legendre, C; Liang, WS; Macy, ME; Martin, L; Meshinchi, S; Narendran, A; Pollard, J; Salhia, B; Triche, TJ; Wai, D | 1 |
| Guo, R; Han, HH; Jiang, ZX; Liu, YF; Sun, H; Wang, M | 1 |
| Fukuda, M; Hosokawa, M; Iwakawa, S; Masuda, A; Tanaka, S; Ueda, K | 1 |
| Al-Ali, HK; Beach, CL; Butrym, A; Candoni, A; Cavenagh, J; Del Castillo, TB; Döhner, H; Dombret, H; Falantes, J; Jang, JH; Kumar, R; Minden, MD; Récher, C; Sandhu, I; Schuh, AC; Selleslag, D; Seymour, JF; Songer, S; Stone, RM; Weaver, J; Wierzbowska, A | 1 |
| Guo, XZ; Huang, YQ; Pan, JX; Wu, SX; Zhang, XY | 1 |
| Andreeff, M; Benton, CB; Boddu, P; Borthakur, G; Cortes, J; Daver, N; DiNardo, CD; Garcia-Manero, G; Jabbour, EJ; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Konopleva, M; Patel, K; Ravandi, F; Takahashi, K | 1 |
| DU, Y; Jing, Y; Li, PF; Liu, M; Peng, CJ; Sun, JZ; Wang, ZH; Yao, YB; Zhou, HW; Zhou, MH | 1 |
| Füreder, W; Gleixner, K; Grünberger, B; Hoermann, G; Kornauth, C; Schwarzinger, I; Sperr, WR; Thalhammer, R; Valent, P | 1 |
| Hiraga, J; Kagami, Y; Narita, M; Suzuki, N; Takagi, Y; Tomita, A | 1 |
| Arellano, M; Carlisle, JW | 1 |
| Chen, RA; Chen, Y; Ji, YR; Li, GH; Liu, C; Liu, L; Qin, WW; Wang, WQ; Zhou, NC | 1 |
| Konopleva, M; Letai, A | 1 |
| Al-Ali, HK; Beach, CL; Bullinger, L; Del Castillo, TB; Döhner, H; Dolnik, A; Dombret, H; MacBeth, KJ; Minden, MD; Santini, V; Seymour, JF; Skikne, BS; Songer, S; Stone, RM; Tang, L; Tu, N; Vyas, P | 1 |
| Appelbaum, FR; Erba, HP; Estey, E; Garcia-Manero, G; Nand, S; Othus, M; Sekeres, MA | 1 |
| Al Yacoub, R; Cronin, TL; Griffiths, EA; Miller, A; Ontiveros, EP; Thompson, JE; Vachhani, P; Wang, ES; Zhang, F | 1 |
| Cook, JR; Nomani, L; Rogers, HJ | 1 |
| Flaishon, L; Rowe, JM; Stone, A; Yakar, RB; Zukerman, T | 1 |
| Cortes, JE; Graef, T; Jonas, BA; Luan, Y; Stein, AS | 1 |
| Agarwal, S; Friedel, A; Gopalakrishnan, S; Hayslip, J; Kirschbrown, W; Menon, R; Mensing, S; Potluri, J; Salem, AH | 1 |
| Artz, AS; Cahill, KE; Fulton, N; Godley, LA; Green, M; Jain, N; Kadri, S; Karimi, YH; Karrison, TG; Larson, RA; Le Beau, MM; Liu, H; McNerney, ME; Odenike, O; Segal, J; Stock, W; Thirman, MJ; Weiner, H | 1 |
| Antunovic, P; Cammenga, J; Deneberg, S; Derolf, ÅR; Eriksson, A; Höglund, M; Juliusson, G; Lazarevic, V; Lehmann, S; Lorenz, F; Möllgård, L; Ölander, E; Österroos, A; Uggla, B; Wennström, L | 1 |
| Carraway, HE; Chandhok, NS; Griffiths, EA; Prebet, T | 1 |
| Andrews, C; Maze, D; Murphy, T; Sibai, H | 1 |
| Asaro, G; De Luca, A; Delfini, M; Guglielmi, G; Iavicoli, S; Sciubba, F; Spagnoli, M | 1 |
| Liu, C; Shao, Z; Sun, Y; Wu, C | 1 |
| Beutel, G; Eder, M; Gabdoulline, R; Gohring, G; Heuser, M; Koenecke, C; Krauter, J; Markel, D; Schlegelberger, B; Shahswar, R; Stadler, M; Thol, F; Trummer, A | 1 |
| Anderson, JT; Baker, SD; Buelow, DR; Gibson, AA; Goodwin, EA; Hu, S; Lamba, JK; Pounds, SB; Shi, L; Sparreboom, A | 1 |
| Bai, J; Lian, X; Pei, Z; Song, Q; Wang, H; Wang, J; Zhang, B | 1 |
| Gangat, N; Tefferi, A | 1 |
| Boenisch, O; Bokemeyer, C; Fiedler, W; Ghandili, S; Ittrich, H; Jarczak, D; Karagiannis, P; Kluge, S; Lütgehetmann, M; Modemann, F; Pfefferle, S; Roedl, K; Rohde, H; Schmiedel, S; Sonnemann, P; Weisel, K; Wichmann, D | 1 |
| He, HS; Hua, JS; Li, F; Ma, IX; Wang, XH; Wang, XQ; Wu, M; Xie, YH; Yang, RY; Ye, XJ | 1 |
| Feld, J; Navada, SC; Silverman, LR | 1 |
| Foster, MC; Green, SD; Richardson, DR; Zeidner, JF | 1 |
| Algarra, L; Amador Barciela, ML; Barragán, E; Bergua Burgues, J; Colorado, M; Falantes, JF; Fernández, MÁ; Foncillas, MÁ; García, O; Gascón, A; Gil, C; Herrera, P; Labrador, J; Lavilla, E; López-Lorenzo, JL; Martínez-Cuadrón, D; Martínez-López, J; Martínez-Sánchez, MP; Montesinos, P; Olave, MT; Paiva, B; Pérez-Encinas, MM; Ramos, F; Rodríguez-Veiga, R; Salamero, O; Sanz, MÁ; Sayas, MJ; Serrano, A; Serrano, J; Simiele, A; Tormo, M; Vidriales, B; Vives, S | 1 |
| Perl, AE | 1 |
| Alvarado, Y; Andreeff, M; Borthakur, G; Cortes, JE; Daver, N; DiNardo, CD; Estrov, Z; Ferrajoli, A; Garcia-Manero, G; Guerra, V; Jabbour, EJ; Jain, N; Kadia, T; Kantarjian, HM; Konopleva, M; Levis, M; Ohanian, M; Pemmaraju, N; Pierce, S; Pinsoy, MR; Ravandi, F; Swaminathan, M; Wierda, WG; Xiao, L | 1 |
| Azenkot, T; Jonas, BA; Moskoff, BN; Othman, TA; Tenold, ME | 1 |
| Al-Ammari, M; Albtoosh, BM; Alfayez, M; AlGhamdi, MS; Alnoamani, MS; AlShehry, NF; Altaf, SY; Aoun, SMA; Iqbal, S; Marei, MA; Motabi, IH; Tailor, IK; Zaidi, SZ | 1 |
| Assis-Mendonça, GR; Bueno, MLP; da Silva, JAF; Duarte, ASS; Ferro, KP; Pericole, FV; Rego, EM; Roversi, FM; Saad, STO; Shiraishi, RN; Torello, CO | 1 |
| Argüello, RJ; Aroua, N; Avet-Loiseau, H; Boet, E; Bosc, C; Bousard, A; Cabon, F; Cognet, G; Farge, T; Fournié, JJ; Fovez, Q; Gadaud, N; Gotanègre, M; Jarrou, L; Joffre, C; Kaoma, T; Kaphan, E; Kluza, J; Larrue, C; Marine, JC; Mazzotti, C; Mouchel, PL; Nicot, N; Picard, M; Poillet-Perez, L; Polley, N; Rambow, F; Récher, C; Sabatier, M; Sahal, A; Saland, E; Sarry, JE; Stuani, L; Su, X; Tamburini, J; Tiong, IS; Tosolini, M; Vergez, F; Wang, Y; Wei, AH | 1 |
| Ando, J; Delgado, A; Duan, Y; Eto, T; Garbayo Guijarro, B; Imada, K; Ishikawa, Y; Ito, T; Katsuoka, Y; Kawakami, Y; Kiyoi, H; Kizaki, M; Komeno, T; Kondo, T; Llamas, C; Miyamoto, T; Mori, A; Morita, T; Morita, Y; Nakayama, M; Satake, A; Takezako, N; Taneike, I; Uoshima, N; Watanabe, J; Yamamoto, K; Yoshida, C | 1 |
| Babushok, DV; Bruno, XJ; Carroll, MP; Frey, NV; Gill, SI; Hexner, EO; Hwang, WT; Loren, AW; Luger, SM; Maillard, IP; Margolis, D; Martin, ME; Matthews, AH; McCurdy, SR; Paralkar, VR; Perl, AE; Porter, DL; Pratz, KW; Stadtmauer, EA | 1 |
| Arrigo, G; Audisio, E; Cerrano, M; D'Ardìa, S; Frairia, C; Freilone, R; Giai, V; Secreto, C; Urbino, I | 1 |
| Andreeff, M; Bhalla, KN; Borthakur, G; Daver, NG; DiNardo, CD; Ferrajoli, A; Garcia-Manero, G; Issa, GC; Jabbour, E; Jain, N; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, HM; Konopleva, MY; Malla, R; Montalban-Bravo, G; Ohanian, M; Pemmaraju, N; Popat, UR; Quagliato, K; Rausch, CR; Ravandi, F; Reville, PK; Sasaki, K; Short, NJ; Takahashi, K; Wang, X | 1 |
| Ai, J; Arnall, J; Avalos, BR; Boselli, D; Chen, T; Chiad, Z; Chojecki, AL; Copelan, EA; Cruz, A; DiSogra, KY; Grunwald, MR; Karabinos, A; Knight, TG; Patel, R; Ragon, BK; Sanikommu, SR; Shah, NA; Symanowski, J; Verbyla, A | 1 |
| Al Jammal, M; Al-Juhaishi, T; Al-Kindi, SG; Arora, S; Badhwar, A; Chahine, N; Chami, T; Hajjari, J; Heisler, AC; Hoit, BD; Janus, SE; Mously, H | 1 |
| Kobayashi, M; Kosugi, N; Suzaki, K; Yasu, T | 1 |
| Belhabri, A; Bertoli, S; Billotey, NC; Bulabois, C; Cartet, E; Dumas, PY; Fornecker, L; Giltat, A; Guepin, GR; Guerineau, E; Houyou, D; Hunault, M; Kaphan, E; Lachenal, F; Laloi, L; Laribi, K; Michallet, AS; Michallet, M; Michel, C; Morisset, S; Paul, F; Pigneux, A; Puisset, F; Récher, C; Rocher, C; Santagostino, A; Simand, C; Simonet, MB; Tabrizi, R; Villate, A | 1 |
| Hou, JX; Hu, YM; Li, SZ; Lin, D; Liu, KQ; Mi, YC; Wang, JX; Wang, Y; Wei, H; Wei, SN; Zhang, GJ; Zhou, CL | 1 |
| Cahill, K; Chen, C; Fulton, N; Han, D; He, C; Liang, G; Odenike, O; Stock, W; Wang, L; You, Q; Zhang, W | 1 |
| Azab, M; Brandwein, J; Demeter, J; Döhner, H; Döhner, K; Fenaux, P; Gercheva-Kyuchukova, L; Gobbi, M; Griffiths, E; Hao, Y; Issa, JJ; Jedrzejczak, WW; Kantarjian, H; Keer, H; Krauter, J; Kropf, PL; Mayer, J; Min, YH; Miyazaki, Y; Novak, J; Ojeda-Uribe, M; Robak, T; Roboz, GJ; Thomas, X; Yee, K; Yeh, SP | 1 |
| Chan, G; Cortes, JE; DiRienzo, CG; Dombret, H; Jeyakumar, D; Jou, E; Liu, X; Ma, W; Mayer, J; Merchant, A; Montesinos, P; Novak, J; O'Brien, T; Robak, T; Roh, W; Sekeres, MA; Shaik, N; Taussig, DC; Tomlinson, B; Wang, J | 1 |
| Betts, KA; Bui, CN; Dua, A; Lachaine, J; Li, X; Pratz, K; Schuh, AC; Song, J; Suh, HS | 1 |
34 review(s) available for azacitidine and cytarabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The structure of nucleosides in relation to their biological and and biochemical activity: a summary.
Topics: 3-Deazauridine; Adenine; Adenosine; Anti-Bacterial Agents; Azacitidine; Cytarabine; Idoxuridine; Isopentenyladenosine; Nucleosides; Pseudouridine; Puromycin; Structure-Activity Relationship; Tubercidin; Uridine | 1975 |
Antineoplastic drugs: clinical pharmacology and therapeutic use.
Topics: Alkaloids; Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Azacitidine; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Drug Interactions; Fluorouracil; Humans; Kinetics; Methotrexate; Podophyllotoxin | 1978 |
Augmentation of hemoglobin synthesis by S-phase specific drugs in the K562 cell line.
Topics: Adult; Azacitidine; Cell Line; Cytarabine; Deoxyribonuclease HpaII; DNA Restriction Enzymes; Fetal Hemoglobin; Globins; Hemoglobinopathies; Humans; Hydroxyurea; Interphase; Kinetics; Transcription, Genetic | 1985 |
Cell kinetics as related to treatment of patients with acute nonlymphoid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Bone Marrow Cells; Cell Cycle; Child; Cytarabine; Daunorubicin; Doxorubicin; Etoposide; Flow Cytometry; Hematopoietic Stem Cells; Humans; Hydrocortisone; Leukemia; Methotrexate; Mitotic Index; Neoplastic Stem Cells; Prednisone; Prognosis; Vincristine | 1985 |
Intercalator-induced, topoisomerase II-mediated DNA cleavage and its modification by antineoplastic antimetabolites.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Azacitidine; Cell Survival; Cytarabine; DNA; DNA Topoisomerases, Type II; Drug Synergism; Humans; Hydroxyurea; In Vitro Techniques; Intercalating Agents; Mice | 1986 |
Antimetabolites.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Floxuridine; Fluorouracil; Folic Acid Antagonists; Humans; Mercaptopurine; Methotrexate; Purines; Thioguanine | 1987 |
New cancer chemotherapeutic agents.
Topics: Aldehydes; Amides; Amines; Animals; Antineoplastic Agents; Asparaginase; Azacitidine; Azaguanine; Bleomycin; Carmustine; Chlorides; Cyclization; Cyclohexanes; Cytarabine; Cytidine; Doxorubicin; Glycosides; Humans; Hydroxyurea; Imidazoles; Leukemia, Lymphoid; Leukemia, Myeloid; Mice; Nitrosourea Compounds; Picolinic Acids; Platinum; Podophyllotoxin; Streptozocin; Thiosemicarbazones; Triazenes | 1972 |
Resistance of mammalian tumour cells toward pyrimidine analogues. A review.
Topics: Animals; Antimetabolites; Azacitidine; Azauridine; Bromouracil; Carcinoma, Ehrlich Tumor; Cell Line; Cricetinae; Cytarabine; Deoxycytidine; Drug Resistance; Fluorouracil; Genetic Code; Leukemia, Experimental; Leukemia, Lymphoid; Mast-Cell Sarcoma; Mice; Mutation; Neoplasms, Experimental; Oncogenic Viruses; Phosphotransferases; Pyrimidines; Sarcoma, Experimental; Selection, Genetic; Thymidine Kinase; Uracil; Virus Replication | 1973 |
Thymidine as an anticancer agent, alone or in combination. A biochemical appraisal.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; Drug Therapy, Combination; Fluorouracil; Humans; Methotrexate; Neoplasms; Thymidine | 1982 |
Differentiation therapy of myelodysplastic syndromes: fact or fiction?
Topics: Acetamides; Amifostine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arginine; Azacitidine; Butyrates; Cholecalciferol; Cytarabine; Harringtonines; Hematopoietic Cell Growth Factors; Heme; Homoharringtonine; Humans; Interferons; Myelodysplastic Syndromes; Retinoids | 1998 |
Chemoprotection against cytosine nucleoside analogs using the human cytidine deaminase gene.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Cytidine Deaminase; Decitabine; Deoxycytidine; Drug Resistance; Gemcitabine; Humans | 1999 |
Acute myeloid leukemia in the elderly: conventional and novel treatment approaches.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Azacitidine; Clofarabine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Oxides; Recurrence; Sulfonamides | 2008 |
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Cytarabine; Disease Progression; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Quality of Life; Risk Assessment; Sickness Impact Profile | 2012 |
Current treatment of acute myeloid leukemia.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Consolidation Chemotherapy; Cytarabine; Decitabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Precision Medicine; Stem Cell Transplantation | 2012 |
The euphoria of hypomethylating agents in MDS and AML: is it justified?
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; DNA Methylation; Endpoint Determination; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Patient Selection; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Treatment Outcome | 2013 |
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
Decitabine. Acute myeloid leukaemia: no progress.
Topics: Age Factors; Aged; Animals; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Patient Selection; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome | 2014 |
Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Critical Care; Cytarabine; Decitabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Organophosphates; Quinazolines; Quinolones | 2015 |
D-CAG (decitabine followed by cytarabine, aclarubicin, and G-CSF) for relapsed acute myeloid leukemia after hematopoietic cell transplantation.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Young Adult | 2016 |
How I treat older patients with acute myeloid leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Prognosis; Remission Induction; Survival Rate; Transplantation, Homologous | 2018 |
BCL-2 inhibition in AML: an unexpected bonus?
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2018 |
Efficacy outcomes in the treatment of older or medically unfit patients with acute myeloid leukaemia: A systematic review and meta-analysis.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis; Treatment Outcome | 2019 |
Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Pyridines; Recurrence; Remission Induction; Staurosporine; Sulfonamides | 2020 |
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides | 2020 |
Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Decitabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Sulfonamides | 2020 |
Forsaken Pharmaceutical: Glasdegib in Acute Myeloid Leukemia and Myeloid Diseases.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzimidazoles; Cell Line, Tumor; Clinical Trials as Topic; Cytarabine; Drug Approval; Drug Evaluation, Preclinical; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mice; Phenylurea Compounds; Signal Transduction; Smoothened Receptor; United States | 2021 |
Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
Topics: Animals; Antineoplastic Agents; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Prognosis; Sulfonamides | 2021 |
Which novel agents will have a clinically meaningful impact in AML at diagnosis?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Humans; Leukemia, Myeloid, Acute | 2021 |
An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2021 |
Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature.
Topics: Aged; Aniline Compounds; Azacitidine; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Pyrazines; Recurrence | 2022 |
Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database.
Topics: Adolescent; Adult; Aminopyridines; Anthracyclines; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Cytarabine; Decitabine; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Pericarditis; Pharmacovigilance; Sulfonamides; Triazines; United States; United States Food and Drug Administration | 2022 |
Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bayes Theorem; Cytarabine; Humans; Leukemia, Myeloid, Acute; Network Meta-Analysis; Treatment Outcome | 2023 |
46 trial(s) available for azacitidine and cytarabine
| Article | Year |
|---|---|
Feasibility and efficacy of 5-azacytidine used early in the therapy of adult acute nonlymphocytic leukemia: an ECOG pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission, Spontaneous; Time Factors | 1979 |
Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital.
Topics: 2-Chloroadenosine; Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Cladribine; Cytarabine; Daunorubicin; Deoxyadenosines; Etoposide; Humans; Infant; Leukemia, Myeloid, Acute; Remission Induction | 1992 |
Intensive sequential chemotherapy for children with acute myelogenous leukemia: VAPA, 80-035, and HI-C-Daze.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain; Child; Child, Preschool; Cytarabine; Doxorubicin; Etoposide; Humans; Infant; Leukemia, Myeloid, Acute; Prednisolone; Survival Analysis; Vincristine | 1992 |
Preliminary results of intensive therapy of children and adolescents with acute nonlymphocytic leukemia--a Childrens Cancer Study Group report.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Humans; Infant; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Pilot Projects; Randomized Controlled Trials as Topic; Remission Induction; Thioguanine; Vincristine | 1990 |
Remission induction and postremission therapy in acute myelogenous leukemia: British MRC Study.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Doxorubicin; Drug Combinations; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Nimustine; Prednisone; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Thioguanine; United Kingdom; Vincristine | 1990 |
A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Belgium; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; France; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Vincristine | 1990 |
Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Germany, West; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate | 1990 |
Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Doxorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Sex Factors; Survival Analysis | 1990 |
Induction failures in childhood acute nonlymphocytic leukemia: etoposide/5-azacytidine for cases refractory to daunorubicin/cytarabine.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia; Male | 1986 |
Intensive induction and consolidation chemotherapy for adults and children with acute myeloid leukaemia (AML) joint AML trial 1982-1985.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Random Allocation; Remission Induction; Risk; Thioguanine; United Kingdom | 1987 |
The ninth British Medical Research Council trial for the treatment of acute myeloid leukaemia.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Combinations; England; Etoposide; Humans; Leukemia, Myeloid, Acute; Prednisone; Remission Induction; Thioguanine; Vincristine | 1987 |
Improvement in outcome for children with acute nonlymphocytic leukemia. A report from the Childrens Cancer Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Humans; Infant; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Prednisolone; Prognosis; Remission Induction; Thioguanine; Vincristine | 1989 |
[AML-6 study of the value of cyclic alternating chemotherapy during remission in acute myelocytic leukemia].
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Administration Schedule; Humans; Leukemia, Myeloid, Acute; Middle Aged; Vincristine | 1985 |
Contrasting benefits of two maintenance programs following identical induction in children with acute nonlymphocytic leukemia: a report from the Childrens Cancer Study Group.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Cyclophosphamide; Cytarabine; Humans; Leukemia; Thioguanine; Vincristine | 1984 |
A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; BCG Vaccine; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Daunorubicin; Deoxyguanosine; Female; Humans; Immunotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Random Allocation; Thioguanine; Thionucleosides; United States | 1984 |
Long-term outcome of postremission chemotherapy for adults with acute myeloid leukemia using different dose-intensities.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Germany; Humans; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Opportunistic Infections; Patient Acceptance of Health Care; Preleukemia; Prospective Studies; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Vincristine | 1994 |
Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Patient Selection; Remission Induction; Thioguanine | 1995 |
Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Treatment Outcome | 2010 |
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Drug Administration Schedule; Erythrocyte Transfusion; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Survival Analysis; Treatment Outcome | 2010 |
Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Decitabine; Diarrhea; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Humans; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome; Young Adult | 2011 |
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytarabine; Cytokines; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Niacinamide; Oxides; Phenylurea Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib | 2011 |
Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
Topics: Adenine Nucleotides; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Azacitidine; Clofarabine; Consolidation Chemotherapy; Cytarabine; Decitabine; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome | 2012 |
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Choice Behavior; Cytarabine; Decision Making; Decitabine; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Neutropenia; Palliative Care; Patient Participation; Remission Induction; Risk Assessment; Risk Factors; Thrombocytopenia; Treatment Outcome | 2012 |
Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
Topics: Aclarubicin; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Survival; Cyclin-Dependent Kinase Inhibitor p15; Cytarabine; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Tumor Cells, Cultured; Young Adult | 2012 |
Azacitidine-eligibility in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukaemia: a registry-based study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Registries; Retrospective Studies | 2013 |
Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Feasibility Studies; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Pilot Projects; Survival Analysis; Treatment Outcome | 2012 |
Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hydroxamic Acids; In Vitro Techniques; Middle Aged; Myelodysplastic Syndromes; Nausea; Neutropenia; Recurrence; Risk Factors; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting; Vorinostat | 2014 |
Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Cytogenetic Analysis; Decitabine; Female; Humans; Internationality; Leukemia, Myeloid, Acute; Male; Multivariate Analysis; Risk Factors; Treatment Outcome | 2014 |
Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Decitabine; Dexamethasone; DNA Methylation; DNA, Neoplasm; Doxorubicin; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Hyperglycemia; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Vincristine; Young Adult | 2014 |
Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia.
Topics: Aclarubicin; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Prospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Azacitidine; Clofarabine; Cytarabine; Decitabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Remission Induction; Treatment Outcome | 2015 |
A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Female; Humans; Induction Chemotherapy; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Pilot Projects; Remission Induction; Survival Analysis; Thrombocytopenia | 2015 |
Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Cytogenetic Analysis; Daunorubicin; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis | 2016 |
Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Glycine; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Treatment Outcome | 2016 |
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers; Cytarabine; Decitabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Recurrence; Treatment Outcome; Young Adult | 2017 |
A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.
Topics: Adolescent; Azacitidine; Child; Child, Preschool; Cytarabine; Daunorubicin; Decitabine; DNA Methylation; Epigenesis, Genetic; Etoposide; Female; Humans; Induction Chemotherapy; Infant; Leukemia, Myeloid, Acute; Male; Promoter Regions, Genetic; Treatment Outcome | 2017 |
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Prognosis; Treatment Outcome | 2017 |
Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Cytarabine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Non-Randomized Controlled Trials as Topic; Piperidines; Prognosis; Pyrazoles; Pyrimidines; Remission Induction; Survival Rate | 2019 |
A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia.
Topics: Aged; Azacitidine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Nucleophosmin; Remission Induction | 2020 |
[Comparison of the Curative Efficacy of Elderly Patients with High-Risk MDS and MDS-Transformed AML between Decitabine Combined with Low-Dose CEG Regimen and Decitabine Combined with Low-Dose CAG Regimen].
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prospective Studies; Treatment Outcome | 2020 |
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Remission Induction; Treatment Outcome; Vidarabine | 2021 |
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
Topics: Azacitidine; Benzothiazoles; Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Myelodysplastic Syndromes; Phenylurea Compounds | 2021 |
Efficacy and Safety of Azacytidine in Combination With Fludarabine and High-Dose Cytarabine With G-CSF (FLAG) in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.
Topics: Adolescent; Adult; Azacitidine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine; Young Adult | 2021 |
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged | 2022 |
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study.
Topics: Azacitidine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Treatment Outcome | 2023 |
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Nausea | 2023 |
184 other study(ies) available for azacitidine and cytarabine
| Article | Year |
|---|---|
Synthesis and antitumor activity of 5-azacytosine arabinoside.
Topics: Animals; Antineoplastic Agents; Azacitidine; Chemical Phenomena; Chemistry; Leukemia L1210; Mice; Stereoisomerism | 1979 |
Structure-activity relationships of antineoplastic agents in multidrug resistance.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Cricetinae; Dactinomycin; Drug Resistance; Leukemia L1210; Mice; Regression Analysis; Structure-Activity Relationship; Tumor Cells, Cultured | 1990 |
Synthesis and antitumor activity of fluorine-substituted 4-amino-2(1H)-pyridinones and their nucleosides. 3-Deazacytosines.
Topics: Animals; Antimetabolites, Antineoplastic; Cytosine; Drug Evaluation, Preclinical; Indicators and Reagents; Leukemia L1210; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Spectrophotometry; Structure-Activity Relationship | 1987 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Chemotherapeutic drugs increase killing of tumor cells by antibody and complement.
Topics: Animals; Antigen-Antibody Reactions; Antineoplastic Agents; Azacitidine; Carcinoma, Hepatocellular; Cell Line; Complement System Proteins; Cyclophosphamide; Cytarabine; Fluorouracil; Guinea Pigs; Liver Neoplasms; Methotrexate; Neoplasms, Experimental; Nitrosamines; Vincristine | 1975 |
The clinical pharmacology of antineoplastic agents (second of two parts).
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Azacitidine; Bleomycin; Carmustine; Cell Nucleus; Chemical Phenomena; Chemistry; Cyclohexanes; Cyclophosphamide; Cytarabine; DNA, Neoplasm; Doxorubicin; Humans; Neoplasms; Nitrosourea Compounds | 1975 |
Cellular phosphorylation of 1-beta-D-arabinofuranosylcytosine 5-azacytidine with intact fibrosarcoma and leukemic cells.
Topics: Animals; Azacitidine; Binding, Competitive; Cells, Cultured; Cricetinae; Cytarabine; Cytidine; Deoxycytidine; Drug Resistance; Fibrosarcoma; Kinetics; Leukemia, Experimental; Mice; Phosphorus; Sarcoma, Experimental | 1975 |
[New drugs for the therapy of acute leukemia].
Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Cytarabine; Daunorubicin; Doxorubicin; Drug Therapy, Combination; Guanazole; Humans; Leukemia; Lomustine; Peptichemio; Podophyllotoxin; Razoxane; Zinostatin | 1975 |
Cytidine deaminase: a new genetic polymorphism demonstrated in human granulocytes.
Topics: Azacitidine; Cytarabine; Cytidine; Cytidine Deaminase; Cytosine; Electrophoresis, Starch Gel; Female; Granulocytes; Humans; Leukocytes; Male; Nucleoside Deaminases; Pedigree; Phenotype; Polymorphism, Genetic | 1975 |
In vitro biochemical and cytotoxicity studies with 1-beta-D-arabinofuranosylcytosine and 5-azacytidine in combination.
Topics: Antineoplastic Agents; Azacitidine; Cell Division; Cells, Cultured; Cytarabine; DNA, Neoplasm; Drug Combinations; Fibrosarcoma; Time Factors | 1975 |
Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes.
Topics: Azacitidine; Blood Proteins; Cell Separation; Cell-Free System; Cytarabine; Cytidine Deaminase; Deoxycytidine; Granulocytes; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Molecular Weight; Phosphates; Phosphotransferases; Tissue Extracts; Uridine Kinase | 1975 |
Enhancing effect by metabolic inhibitors on the killing of tumor cells by antibody and complement.
Topics: Animals; Antibodies, Neoplasm; Antigen-Antibody Reactions; Antineoplastic Agents; Azacitidine; Carcinoma, Hepatocellular; Cells, Cultured; Complement System Proteins; Cyclophosphamide; Cytarabine; Dactinomycin; Doxorubicin; Fluorouracil; Guinea Pigs; Hydroxyurea; Liver Neoplasms; Mercaptopurine; Methotrexate; Mitomycins; Neoplasms, Experimental; Puromycin; Vincristine | 1975 |
Character of the stimulatory response of uridine kinase in rat livers to cycloheximide treatment.
Topics: Animals; Azacitidine; Cycloheximide; Cytarabine; Dactinomycin; Enzyme Activation; Hydroxyurea; Kinetics; Liver; Male; Mitomycins; Phosphotransferases; Puromycin; Rats; Starvation; Uridine Kinase | 1975 |
On the interaction of 3,4,5,6-tetrahydrouridine with human liver cytidine deaminase.
Topics: Azacitidine; Binding Sites; Cytarabine; Cytidine Deaminase; Humans; Kinetics; Liver; Nucleoside Deaminases; Protein Binding; Tetrahydrouridine; Uridine | 1975 |
Biochemical pharmacology of cytidine analog metabolism in human leukemic cells.
Topics: Acute Disease; Adolescent; Adult; Aged; Azacitidine; Cytarabine; Cytidine Deaminase; Humans; In Vitro Techniques; Leukemia; Middle Aged; Phosphotransferases; Uridine Kinase | 1975 |
A new hamster fibrosarcoma model for in vitro/in vivo evaluation of cancer chemotherapeutic agents.
Topics: Ancitabine; Animals; Antineoplastic Agents; Azacitidine; Cell Division; Cell Line; Cells, Cultured; Clone Cells; Cricetinae; Cytarabine; Disease Models, Animal; Drug Therapy, Combination; Female; Fibrosarcoma; Mesocricetus; Sarcoma, Experimental | 1976 |
The therapy of acute leukemia in the adult: a progress report.
Topics: Acute Disease; Adult; Antineoplastic Agents; Azacitidine; Blood Transfusion; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Granulocytes; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Patient Isolation; Platelet Transfusion; Pneumonia; Prednisone; Pyrimethamine; Remission, Spontaneous; Thioguanine; Vincristine; Zinostatin | 1976 |
Symptomatic hypophosphatemia secondary to 5-azacytidine therapy of acute nonlymphocytic leukemia.
Topics: Adult; Azacitidine; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Phosphates; Prednisone; Pregnancy; Pregnancy Complications; Thioguanine; Vincristine | 1976 |
Alterations in differentiation and pyrimidine pathway enzymes in 5-azacytidine resistant variants of a myoblast line.
Topics: Adenosine; Animals; Aspartate Carbamoyltransferase; Azacitidine; Azaguanine; Bromodeoxyuridine; Cell Differentiation; Cell Fusion; Cell Line; Cytarabine; Cytidine Deaminase; Drug Resistance; Genetic Variation; Muscles; Nucleoside Deaminases; Orotate Phosphoribosyltransferase; Orotidine-5'-Phosphate Decarboxylase; Ouabain; Phosphotransferases; Rats; Theophylline; Thymidine; Uridine; Uridine Kinase | 1977 |
Clinical pharmacology of anticancer drugs.
Topics: Animals; Antineoplastic Agents; Azacitidine; Bleomycin; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Doxorubicin; Female; Fluorouracil; Heart; Humans; Leucovorin; Lung; Male; Methotrexate; Neoplasms; Nitrosourea Compounds; Procarbazine; Triazenes; Vinblastine; Vincristine | 1977 |
Separation of leukemic cells into proliferative and quiescent subpopulations by centrifugal elutriation.
Topics: Azacitidine; Bone Marrow; Cell Division; Cell Separation; Centrifugation; Cytarabine; Humans; In Vitro Techniques; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Thymidine | 1977 |
The synthesis and antitumor activity of arabinosyl-5-azacytosine.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cytarabine; Leukemia L1210; Mice | 1977 |
Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase.
Topics: Antineoplastic Agents; Azacitidine; Azepines; Cytarabine; Cytidine; Cytidine Deaminase; Deamination; Decitabine; Humans; Kinetics; Pyrimidine Nucleosides; Tetrahydrouridine | 1992 |
Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498.
Topics: Acute Disease; Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Azacitidine; Child; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Daunorubicin; Down Syndrome; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Methotrexate; Prednisone; Remission Induction; Thioguanine; Vincristine | 1992 |
A comparison of the lethal effects in culture of cytosine arabinoside and arabinofuranosyl-5-azacytosine acting on the blast cells fo acute myeloblastic leukemia.
Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Blast Crisis; Cell Survival; Cytarabine; Humans; Leukemia, Myeloid; Tumor Cells, Cultured | 1992 |
Enhancement of the toxicity and DNA incorporation of arabinosyl-5-azacytosine and 1-beta-D-arabinofuranosylcytosine by cyclopentenyl cytosine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Survival; Colorectal Neoplasms; Cytarabine; Cytidine Triphosphate; Deoxycytosine Nucleotides; DNA, Neoplasm; Humans; In Vitro Techniques; Tumor Cells, Cultured | 1990 |
Comparison of antineoplastic activity of cytosine arabinoside and 5-aza-2'-deoxycytidine against human leukemic cells of different phenotype.
Topics: Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; DNA; Humans; Leukemia; Methylation; Phenotype; Tumor Cells, Cultured | 1990 |
Evidence for allelic exclusion in Chinese hamster ovary cells.
Topics: Alleles; Animals; Azacitidine; Bromodeoxyuridine; Cell Line; Cricetinae; Cricetulus; Cytarabine; Diploidy; DNA; Drug Resistance; Female; Gene Expression; Herpesvirus 1, Equid; Metallothionein; Ovary; Thymidine Kinase; Transformation, Genetic | 1990 |
Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine.
Topics: Azacitidine; Base Sequence; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; DNA, Neoplasm; Drug Resistance; Enzyme Induction; Humans; Kinetics; Leukemia, Experimental; Leukemia, Myeloid; Methylation; Molecular Sequence Data; Time Factors; Tritium; Tumor Cells, Cultured | 1991 |
Human prolactin gene expression: positive correlation between site-specific methylation and gene activity in a set of human lymphoid cell lines.
Topics: Azacitidine; Base Sequence; Cell Line; Cloning, Molecular; Cytarabine; Deoxyribonuclease EcoRI; Deoxyribonuclease HpaII; Deoxyribonucleases, Type II Site-Specific; DNA; Gene Expression; Humans; Lymphocytes; Methylation; Molecular Sequence Data; Nucleic Acid Hybridization; Prolactin | 1990 |
Sequence-dependent interaction of 5-fluorouracil and arabinosyl-5-azacytosine or 1-beta-D-arabinofuranosylcytosine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Division; Cell Line; Cell Nucleus; Cell Survival; Colonic Neoplasms; Cytarabine; Cytidine; Deoxycytosine Nucleotides; DNA, Neoplasm; Drug Administration Schedule; Drug Interactions; Fluorouracil; Humans; Nucleic Acids; Thymine Nucleotides; Tumor Stem Cell Assay | 1991 |
Hb F production in stressed erythropoiesis: observations and kinetic models.
Topics: Anemia; Animals; Azacitidine; Cell Cycle; Cell Differentiation; Cytarabine; Erythropoiesis; Fetal Hemoglobin; Hematopoietic Stem Cells; Humans; Hydroxyurea; Kinetics; Models, Biological; Time Factors; Transcription, Genetic | 1985 |
Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice.
Topics: Animals; Azacitidine; Brain Neoplasms; Cell Line; Cytarabine; Doxorubicin; Humans; Medulloblastoma; Melphalan; Mice; Mice, Nude; Mitoguazone; Neoplasm Transplantation; Nitrosourea Compounds; Skin Neoplasms; Vidarabine Phosphate | 1986 |
Chemotherapy to increase fetal hemoglobin in patients with sickle cell anemia.
Topics: Anemia, Sickle Cell; Azacitidine; Cytarabine; Fetal Hemoglobin; Humans; Hydroxyurea; Kinetics; Thalassemia | 1985 |
Intensive short-term chemotherapy for patients with acute myelogenous leukemia: long-term follow-up.
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Pilot Projects; Thioguanine | 1985 |
Comparison of the activity of arabinosyl-5-azacytosine, arabinosyl cytosine, and 5-azacytidine against intracerebrally implanted L1210 leukemia.
Topics: Animals; Antineoplastic Agents; Azacitidine; Brain Neoplasms; Carmustine; Cytarabine; Leukemia L1210; Mice; Mice, Inbred Strains; Neoplasm Transplantation | 1985 |
On the mechanism of Hb F elevations in the baboon by erythropoietic stress and pharmacologic manipulation.
Topics: Anemia, Hemolytic; Animals; Azacitidine; Cytarabine; DNA; Erythropoiesis; Fetal Hemoglobin; Hemorrhage; Hydroxyurea; Leukocyte Count; Methylation; Nucleic Acid Hybridization; Papio; Reticulocytes | 1986 |
Mechanism of action of 1-beta-D-arabinofuranosyl-5-azacytosine and its effects in L1210 mouse leukemia cells.
Topics: Animals; Antineoplastic Agents; Azacitidine; Bone Marrow; Bone Marrow Cells; Cell Division; Cell Line; Cell Survival; Cytarabine; Decitabine; Drug Evaluation, Preclinical; Kinetics; Leukemia L1210; Leukocyte Count; Male; Mice; Mice, Inbred DBA; Nucleosides; Phosphorylation; Thymidine | 1986 |
3-Deazauridine (NSC 126849): an interesting modulator of biochemical response.
Topics: 3-Deazauridine; Acute Disease; Animals; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; Drug Evaluation; Drug Synergism; Galactosamine; Humans; Kinetics; Leukemia; Neoplasms; Thymidine; Uridine | 1986 |
Determination of the antileukemia agents cytarabine and azacitidine and their respective degradation products by high-performance liquid chromatography.
Topics: Azacitidine; Biotransformation; Chromatography, High Pressure Liquid; Cytarabine; Drug Stability; Humans; Indicators and Reagents; Kinetics; Leukemia; Powders; Spectrophotometry, Ultraviolet | 1986 |
Strong effects of 5-azacytidine on the in vitro lifespan of human diploid fibroblasts.
Topics: 5-Methylcytosine; Azacitidine; Cell Division; Cell Line; Cell Survival; Cytarabine; Cytosine; Decitabine; DNA; Fibroblasts; Humans; Methylation | 1986 |
Interaction of deoxycytidine and deoxycytidine analogs in normal and leukemic human myeloid progenitor cells.
Topics: Azacitidine; Cell Division; Cell Line; Colony-Forming Units Assay; Cytarabine; Decitabine; Deoxycytidine; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute | 1986 |
Thymus involution induced by 5-azacytidine.
Topics: Animals; Azacitidine; Cytarabine; DNA Replication; Dose-Response Relationship, Drug; Kinetics; Male; Organ Size; Rats; Rats, Inbred Strains; Thymus Gland | 1986 |
Antagonism of 5-aza-2'-deoxycytidine antileukemic activity by concomitant treatment with cytarabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Drug Interactions; Leukemia L1210; Male; Mice; Statistics as Topic | 1986 |
Sensitivity to 5-azacytidine of blast progenitors in acute myeloblastic leukemia.
Topics: Azacitidine; Cell Survival; Cells, Cultured; Cytarabine; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Tumor Stem Cell Assay | 1987 |
DNA methylating activity in murine lymphoma cells xenogenized by triazene derivatives.
Topics: Animals; Azacitidine; Carmustine; Cell Line; Cytarabine; Dacarbazine; DNA, Neoplasm; Lymphoma; Male; Methylation; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Quinacrine; Triazenes | 1987 |
Treatment of adults with acute myelogenous leukemia: prospective evaluation of high-dose cytarabine in consolidation chemotherapy and with bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Whole-Body Irradiation | 1987 |
In vitro biochemical tests to evaluate the response to therapy of acute leukemia with cytosine arabinoside or 5-AZA-2'-deoxycytidine.
Topics: Adult; Azacitidine; Cells, Cultured; Child; Cytarabine; Cytidine Deaminase; Decitabine; Deoxycytidine Kinase; DNA Replication; DNA, Neoplasm; Drug Resistance; Humans; In Vitro Techniques; Infant; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Thymidine Kinase | 1987 |
Effect of 5-azacytidine and congeners on DNA methylation and expression of deoxycytidine kinase in the human lymphoid cell lines CCRF/CEM/0 and CCRF/CEM/dCk-1.
Topics: Azacitidine; Cell Line; Cytarabine; Decitabine; Deoxycytidine Kinase; DNA; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance; Humans; Lymphoid Tissue; Methylation; Phosphotransferases | 1987 |
Differential nuclear protein binding to 5-azacytosine-containing DNA as a potential mechanism for 5-aza-2'-deoxycytidine resistance.
Topics: 5-Methylcytosine; Animals; Azacitidine; Cell Line; Cell Nucleus; Cytarabine; Cytosine; Decitabine; DNA; DNA (Cytosine-5-)-Methyltransferases; DNA-Binding Proteins; Drug Resistance; Methylation; Mice | 1987 |
The value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Male; Mercaptopurine; Mitoxantrone; Thioguanine | 1987 |
Differential inhibition of mitogen induced T cell proliferation by 5-azacytidine and cytosine-arabinoside.
Topics: Animals; Azacitidine; Concanavalin A; Cytarabine; DNA; Gene Expression Regulation; Lymphocyte Activation; Male; Methylation; Rats; Rats, Inbred Strains; Spleen; T-Lymphocytes; Thymus Gland | 1988 |
Mechanism of Hb F stimulation by S-stage compounds. In vitro studies with bone marrow cells exposed to 5-azacytidine, Ara-C, or hydroxyurea.
Topics: Azacitidine; Bone Marrow Cells; Cytarabine; Erythropoiesis; Fetal Hemoglobin; Hematopoietic Stem Cells; Humans; Hydroxyurea; In Vitro Techniques; Interphase | 1988 |
Variable DNA methylation changes during differentiation of human melanoma cells.
Topics: Aphidicolin; Azacitidine; Cell Differentiation; Cell Division; Chromatography, High Pressure Liquid; Cytarabine; Decitabine; Diterpenes; DNA; DNA, Neoplasm; Humans; Hydroxyurea; Methylation; Monophenol Monooxygenase; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1988 |
Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia.
Topics: Animals; Antineoplastic Agents; Azacitidine; Bone Marrow; Cell Cycle; Colony-Forming Units Assay; Cytarabine; Decitabine; DNA; Dose-Response Relationship, Drug; Female; Leukemia, Myeloid; Rats; Rats, Inbred BN; Time Factors | 1988 |
Myogenic differentiation of human rhabdomyosarcoma cells induced in vitro by antineoplastic drugs.
Topics: Antineoplastic Agents; Azacitidine; Cell Differentiation; Cell Division; Cell Fusion; Cisplatin; Cyclophosphamide; Cytarabine; Humans; In Vitro Techniques; Muscles; Myosins; Rhabdomyosarcoma; Tumor Cells, Cultured | 1989 |
Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Azacitidine; Child; Child, Preschool; Cytarabine; Deoxycytidine Kinase; DNA, Neoplasm; Drug Resistance; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation; Humans; Male; Methylation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Tumor Cells, Cultured | 1989 |
Isolation and characterization of a K562 cell line resistant to 1-beta-D-arabinofuranosylcytosine-mediated erythroid induction.
Topics: Azacitidine; Cell Differentiation; Cell Division; Cell Separation; Cytarabine; Drug Resistance; Erythrocytes; Globins; Hemoglobins; RNA, Messenger; Tumor Cells, Cultured | 1989 |
On the induction of fetal hemoglobin by butyrates: in vivo and in vitro studies with sodium butyrate and comparison of combination treatments with 5-AzaC and AraC.
Topics: Aminobutyrates; Animals; Azacitidine; Bone Marrow Cells; Butyrates; Cells, Cultured; Cytarabine; Drug Synergism; Erythroid Precursor Cells; Erythropoiesis; Fetal Hemoglobin; Globins; Humans; In Vitro Techniques; Male; Papio | 1989 |
Chemotherapy of L1210 and L1210/ARA-C leukemia with 5-aza-2'-deoxycytidine and 3-deazauridine.
Topics: 3-Deazauridine; Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line; Cytarabine; Decitabine; Drug Interactions; Drug Resistance; Drug Screening Assays, Antitumor; Leukemia L1210; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Tumor Cells, Cultured | 1989 |
Arabinofuranosyl-5-azacytosine: activity against human tumors in athymic mice.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Transformation, Neoplastic; Cytarabine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Stereoisomerism; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured | 1989 |
A two-stage therapeutic design in the spontaneous AKR lymphoma system.
Topics: Amides; Animals; Antineoplastic Agents; Azacitidine; Cyclic P-Oxides; Cyclophosphamide; Cytarabine; Disease Models, Animal; Drug Combinations; Female; Imidazoles; Lymphoma; Male; Mercaptopurine; Methotrexate; Mice; Mice, Inbred Strains; Oxazines; Prednisone; Remission, Spontaneous; Time Factors; Triazenes; Vincristine | 1972 |
Second Joint Working Conference: National Cancer Institute Chemotherapy Program. Working session report: pharmacology.
Topics: Alkaloids; Animals; Antimetabolites; Antineoplastic Agents; Autoradiography; Azacitidine; Carbazoles; Carbon Isotopes; Cell Line; Cells, Cultured; Cricetinae; Cytarabine; DNA; DNA Nucleotidyltransferases; Dogs; Half-Life; Humans; Leukemia L1210; Lung; Pyridines; RNA | 1972 |
Chromatid breakage: differential effect of inhibitors of DNA synthesis during G 2 phase.
Topics: Animals; Azacitidine; Azaguanine; Cell Line; Chromatids; Chromosome Aberrations; Cricetinae; Cytarabine; Cytidine; DNA; DNA Nucleotidyltransferases; Hydroxyurea; Lung; Mitosis; Oxidoreductases; Pyridines; Ribonucleotides; Thiosemicarbazones; Triazines | 1972 |
Effects of cytosine arabinoside, daunomycin, mithramycin, azacytidine, adriamycin, and camptothecin on mammalian cell cycle traverse.
Topics: Animals; Antineoplastic Agents; Autoradiography; Azacitidine; Camptothecin; Cell Division; Cell Line; Cricetinae; Cytarabine; Daunorubicin; DNA; DNA Replication; Doxorubicin; Mitosis; Plicamycin; Thymidine; Tritium | 1972 |
The enhanced therapeutic effect of cis-platinum (II) diamminodichloride against L1210 leukemia when combined with cyclophosphamide or 1,2-bis(3,5-dioxopiperazine-1-yl)propane or several other antitumor agents.
Topics: Amines; Animals; Antineoplastic Agents; Azacitidine; Camptothecin; Carmustine; Chlorides; Cyclophosphamide; Cytarabine; Drug Synergism; Emetine; Fluorouracil; Ketones; Leukemia L1210; Male; Methotrexate; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Piperazines; Platinum; Propane; Time Factors | 1973 |
Deamination of 5-azacytidine by a human leukemia cell cytidine deaminase.
Topics: Aminohydrolases; Azacitidine; Blood Proteins; Carbon Radioisotopes; Chromatography, Ion Exchange; Cytarabine; Cytidine; Deamination; Humans; In Vitro Techniques; Kinetics; Leukemia, Myeloid; Leukocytes; Spectrophotometry, Ultraviolet | 1973 |
[Antimetabolites in the treatment of acute human leukoses. Mechanism of action and conditioning factors in the cellular response to drugs. II].
Topics: Antimetabolites; Azacitidine; Azaguanine; Azauridine; Cell Membrane Permeability; Cytarabine; DNA, Neoplasm; Fluorouracil; Humans; Immunity, Cellular; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Methotrexate; Purines; Pyrimidines | 1974 |
Comparison of the antileukemic activity of 5-AZA-2'-deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; DNA, Neoplasm; Leukemia L1210; Male; Methylation; Mice; Mice, Inbred BALB C; Mice, Inbred DBA | 1984 |
Comparison of the effectiveness of S phase inhibitors in altering gene expression.
Topics: Animals; Azacitidine; Cell Line; Cell Survival; Cytarabine; Female; Genes; Hydroxyurea; Hypoxanthine Phosphoribosyltransferase; Interphase; Kinetics; Mice; Thymidine; Transcription, Genetic; X Chromosome | 1984 |
Regulation of intracisternal A particles in mouse teratocarcinoma cells: involvement of DNA methylation in transcriptional control.
Topics: Animals; Azacitidine; Cell Differentiation; Cytarabine; DNA, Viral; Gene Expression Regulation; Inclusion Bodies, Viral; Methylation; Mice; RNA, Viral; Teratoma | 1984 |
Combination chemotherapy with Clostridium perfringens phospholipase C and cytosine antimetabolites: complementary inhibition directed at membrane lipids.
Topics: Animals; Azacitidine; Cell Line; Choline; Clostridium; Cytarabine; Leukemia L1210; Membrane Lipids; Mice; Microscopy, Electron, Scanning; Sarcoma 180; Type C Phospholipases | 1983 |
Cellular differentiation, cytidine analogs and DNA methylation.
Topics: Adipose Tissue; Animals; Azacitidine; Cell Differentiation; Cells, Cultured; Cytarabine; Cytidine; Decitabine; Deoxycytidine; DNA; DNA (Cytosine-5-)-Methyltransferases; Methylation; Methyltransferases; Mice; Muscles; Structure-Activity Relationship | 1980 |
Chemotherapy of L1210 leukemia with 5-azacytidine in combination with vincristine, adriamycin, or beta-cytosine arabinoside.
Topics: Animals; Azacitidine; Colony-Forming Units Assay; Cytarabine; Doxorubicin; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Leukemia L1210; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Vincristine | 1981 |
Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Agents; Azacitidine; Child; Child, Preschool; Cytarabine; Decitabine; Dose-Response Relationship, Drug; Drug Evaluation; Hematopoietic System; Humans; Leukemia; Male | 1981 |
Kinetics of deamination of 5-aza-2'-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside.
Topics: 3-Deazauridine; Adult; Arabinofuranosyluracil; Azacitidine; Cytarabine; Cytidine Deaminase; Cytosine; Decitabine; Humans; Kinetics; Liver; Nucleoside Deaminases; Substrate Specificity; Thymidine | 1983 |
Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
Topics: 3-Deazauridine; Animals; Azacitidine; Chromatography, High Pressure Liquid; Cytarabine; Drug Therapy, Combination; Lethal Dose 50; Leukemia L1210; Mice; Mice, Inbred DBA; Purine Nucleotides; Pyrimidine Nucleotides; Uridine | 1983 |
Globin gene studies create a puzzle.
Topics: Anemia, Sickle Cell; Azacitidine; Cell Differentiation; Cytarabine; DNA; Erythropoiesis; Fetal Hemoglobin; Gene Expression Regulation; Hematopoietic Stem Cells; Humans; Hydroxyurea; Interphase; Methylation | 1984 |
Drug resistance in cancer.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Azacitidine; Cisplatin; Cytarabine; Drug Resistance; Fluorouracil; Humans; Methotrexate; Neoplasms | 1984 |
Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Thioguanine; Time Factors | 1984 |
Hemopoietic stem cells: their roles in human leukemia and certain continuous cell lines.
Topics: Azacitidine; Cell Differentiation; Cell Line; Clone Cells; Colony-Forming Units Assay; Cytarabine; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute | 1984 |
Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza-2'-deoxycytidine.
Topics: Azacitidine; Cells, Cultured; Cytarabine; Cytidine Triphosphate; Cytosine Nucleotides; Gene Expression Regulation; Histocompatibility Antigens Class II; HLA-DR Antigens; Humans; Leukemia, Myeloid, Acute | 1984 |
Antileukemic activity of 5-aza-2'-deoxycytidine and cytarabine against intracerebral L1210 murine leukemia.
Topics: Animals; Azacitidine; Brain Neoplasms; Cytarabine; Decitabine; Dose-Response Relationship, Drug; Kinetics; Leukemia L1210; Male; Mice; Mice, Inbred Strains | 1984 |
Polarographic reduction and carcinogenic index tg alpha of 5-aza nucleosides possessing antileukemic activity.
Topics: Antineoplastic Agents; Azacitidine; Carcinogens; Cytarabine; Cytidine; Molecular Structure; Oxidation-Reduction; Polarography; Structure-Activity Relationship | 1993 |
Identification of cytidine deaminase as inhibitor of granulocyte-macrophage colony formation.
Topics: Animals; Azacitidine; Bone Marrow Cells; Cell Division; Cytarabine; Cytidine Deaminase; Deoxycytidine; Deoxyuridine; DNA; Female; Granulocytes; Hematopoietic Stem Cells; Macrophages; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Thymidine | 1994 |
An in situ protocol for measuring the expression of chemically-induced mutations in mammalian cells.
Topics: Animals; Azacitidine; Cell Division; Cell Separation; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance; Leukemia L5178; Mice; Mutagenesis, Site-Directed; Mutagenicity Tests; Mutagens; Phenotype; Reproducibility of Results; Thymidine Kinase; Trifluridine; Tumor Cells, Cultured | 1994 |
Altered queuine modification of transfer RNA involved in the differentiation of human K562 erythroleukemia cells in the presence of distinct differentiation inducers.
Topics: Aspartate-tRNA Ligase; Azacitidine; Butyrates; Butyric Acid; Cell Differentiation; Cell Division; Cell Line; Cytarabine; Guanine; Hemin; Humans; Kinetics; Leukemia, Erythroblastic, Acute; RNA, Transfer, Amino Acyl; RNA, Transfer, Asp; RNA, Transfer, His; RNA, Transfer, Tyr; Time Factors; Tumor Cells, Cultured | 1994 |
Transfection of wild-type deoxycytidine kinase (dck) cDNA into an AraC- and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity.
Topics: Animals; Azacitidine; Base Sequence; Cytarabine; Decitabine; Deoxycytidine Kinase; DNA, Complementary; Drug Resistance; Leukemia, Experimental; Molecular Sequence Data; Phosphorylation; Rats; Recombinant Fusion Proteins; RNA, Messenger; Transfection; Tumor Cells, Cultured | 1995 |
HIV-1 expression induced by anti-cancer agents in latently HIV-1-infected ACH2 cells.
Topics: Antineoplastic Agents; Azacitidine; Base Sequence; CD4-Positive T-Lymphocytes; Cell Line; Cell Survival; Cytarabine; DNA; Fluorouracil; HIV-1; Methotrexate; Methylation; Molecular Sequence Data; NF-kappa B; Phytohemagglutinins; Tetradecanoylphorbol Acetate; Vinblastine | 1995 |
De novo induced mutations in the deoxycytidine kinase (dck) gene in rat leukemic clonal cell lines confer resistance to cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC).
Topics: Animals; Antineoplastic Agents; Azacitidine; Blotting, Southern; Cell Line; Cytarabine; Decitabine; Deoxycytidine Kinase; Drug Resistance; Gene Expression; Kinetics; Leukemia, Experimental; Polymerase Chain Reaction; Polymorphism, Genetic; Rats; Restriction Mapping; Time Factors; Transcription, Genetic; Tumor Cells, Cultured | 1995 |
In vitro-induced resistance to the deoxycytidine analogues cytarabine (AraC) and 5-aza-2'-deoxycytidine (DAC) in a rat model for acute myeloid leukemia is mediated by mutations in the deoxycytidine kinase (dck) gene.
Topics: Animals; Antineoplastic Agents; Azacitidine; Base Sequence; Chromosome Aberrations; Cytarabine; Decitabine; Deoxycytidine Kinase; Drug Resistance; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Molecular Sequence Data; Point Mutation; Polymorphism, Single-Stranded Conformational; Rats; Translocation, Genetic; Tumor Cells, Cultured | 1995 |
Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2'-deoxycytidine.
Topics: Acute Disease; Animals; Antineoplastic Agents; Azacitidine; Binding, Competitive; Cytarabine; Decitabine; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance; In Vitro Techniques; Kinetics; Leukemia, Myeloid; Rats; Rats, Inbred BN; Tumor Cells, Cultured | 1993 |
Evaluation of the antineoplastic activity of adozelesin alone and in combination with 5-aza-2'-deoxycytidine and cytosine arabinoside on DLD-1 human colon carcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzofurans; Carcinoma, Squamous Cell; Cell Division; Colonic Neoplasms; Cyclohexanecarboxylic Acids; Cyclohexenes; Cytarabine; Decitabine; DNA, Neoplasm; Drug Screening Assays, Antitumor; Duocarmycins; Humans; Indoles; Lung Neoplasms; Time Factors; Tumor Cells, Cultured | 1993 |
Cytotoxic activity and mechanism of action of 5-Aza-2'-deoxycytidine in human CML cells.
Topics: Antineoplastic Agents; Azacitidine; Blast Crisis; Cytarabine; Decitabine; DNA, Neoplasm; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Time Factors; Tumor Cells, Cultured | 1993 |
Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells.
Topics: 3T3 Cells; Animals; Antimetabolites; Antimetabolites, Antineoplastic; Azacitidine; Colony-Forming Units Assay; Cytarabine; Cytidine Deaminase; Decitabine; Deoxycytidine; DNA, Complementary; Drug Resistance; Enzyme Inhibitors; Fibroblasts; Gemcitabine; Gene Transfer Techniques; Genetic Vectors; Humans; Mice; Phenotype; Retroviridae; Tetrahydrouridine | 1998 |
Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study
Topics: Adolescent; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Chromosome Aberrations; Chromosome Inversion; Chromosomes, Human; Cohort Studies; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Life Tables; Male; Multicenter Studies as Topic; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Remission Induction; Risk Assessment; Risk Factors; Survival Analysis; Thioguanine; Translocation, Genetic; Treatment Failure; Treatment Outcome; United States | 2000 |
Selection of drug-resistant transduced cells with cytosine nucleoside analogs using the human cytidine deaminase gene.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Cells; Colony-Forming Units Assay; Cytarabine; Cytidine Deaminase; Decitabine; Deoxycytidine; DNA Modification Methylases; Drug Evaluation; Drug Resistance; Enzyme Inhibitors; Flow Cytometry; Gene Transfer Techniques; Genetic Vectors; Green Fluorescent Proteins; Humans; Leukemia; Luminescent Proteins; Retroviridae; Transgenes | 2001 |
Somatic recombination: a major genotoxic effect of two pyrimidine antimetabolitic chemotherapeutic drugs in Drosophila melanogaster.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; Drosophila melanogaster; Female; Male; Molecular Structure; Mutagenicity Tests; Recombination, Genetic | 2002 |
Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene.
Topics: 3T3 Cells; Animals; Azacitidine; Cell Death; Cell Line; Cytarabine; Cytidine Deaminase; Decitabine; Deoxycytidine; Deoxycytidine Kinase; DNA, Complementary; Dose-Response Relationship, Drug; Gemcitabine; Genetic Vectors; Humans; Mice; Phenotype; Phosphorylation; Retroviridae; Thymidine Kinase; Tumor Cells, Cultured | 2002 |
Inactivation of deoxycytidine kinase and overexpression of P-glycoprotein in AraC and daunorubicin double resistant leukemic cell lines.
Topics: 2-Chloroadenosine; Alternative Splicing; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Biological Transport; Buthionine Sulfoximine; Calcium Channel Blockers; Cytarabine; Daunorubicin; Decitabine; Deoxyadenosines; Deoxycytidine Kinase; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Glutathione; Humans; Idarubicin; Leukemia; Methotrexate; Neoplasm Proteins; Rats; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Verapamil | 2003 |
Potentiation of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia.
Topics: Antimetabolites, Antineoplastic; Aphidicolin; Azacitidine; Child; Cyclin-Dependent Kinases; Cytarabine; Decitabine; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Nucleic Acid Synthesis Inhibitors; Ribonucleotide Reductases | 2005 |
Trisomy 19 as the sole chromosomal abnormality in proliferative chronic myelomonocytic leukemia.
Topics: Aged; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 19; Cytarabine; Cytogenetic Analysis; Daunorubicin; Decitabine; Dose-Response Relationship, Drug; Fatal Outcome; Female; Humans; Hydroxyurea; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Phenotype; Steroids; Treatment Outcome | 2006 |
Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.
Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Cytarabine; Daunorubicin; Developing Countries; Disease-Free Survival; Drug Evaluation; Etoposide; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Infant; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Prednisone; Remission Induction; Retrospective Studies; Singapore; Survival Analysis; Thioguanine; Treatment Outcome; Vincristine | 2007 |
Effect of cytarabine and decitabine in combination in human leukemic cell lines.
Topics: Annexin A5; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; DNA Methylation; DNA, Neoplasm; HL-60 Cells; Humans; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
Advances in the management of acute myeloid leukemia in older adult patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Education as Topic; Practice Guidelines as Topic; Prognosis; Quality of Life; Social Support; Stem Cell Transplantation | 2010 |
Nucleoside drugs induce cellular differentiation by caspase-dependent degradation of stem cell factors.
Topics: Azacitidine; Carcinoma, Embryonal; Caspase 7; Caspase Inhibitors; Cell Differentiation; Cell Line, Tumor; Cytarabine; Decitabine; DNA Damage; DNA Methylation; Enzyme Inhibitors; Humans; JNK Mitogen-Activated Protein Kinases; Neurons; Octamer Transcription Factor-3; Polycomb-Group Proteins; Protein Processing, Post-Translational; Protein Stability; Repressor Proteins; Stem Cell Factor | 2010 |
Prodrugs of aza nucleosides based on proton transfer reaction.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; Drug Design; Hydrogen Bonding; Kinetics; Myelodysplastic Syndromes; Nucleosides; Prodrugs; Protons; Thermodynamics | 2010 |
p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Blotting, Western; Cell Differentiation; Cytarabine; Decitabine; DNA Damage; Electrophoresis, Polyacrylamide Gel; Epigenesis, Genetic; Genes, p53; Humans; Leukemia, Myeloid, Acute; Mice; Phosphorylation; Transplantation, Heterologous | 2011 |
Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Disease Progression; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Pilot Projects; Treatment Outcome | 2012 |
Increased proliferation and chemosensitivity of human mesenchymal stromal cells expressing fusion yeast cytosine deaminase.
Topics: Adipose Tissue; Apoptosis; Azacitidine; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Cytarabine; Cytosine Deaminase; Drug Screening Assays, Antitumor; Female; Fluorouracil; Genetic Engineering; Green Fluorescent Proteins; Humans; Mesenchymal Stem Cells; Recombinant Fusion Proteins; Retroviridae; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Transduction, Genetic; Transgenes | 2012 |
Over-expression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34+ cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Transformation, Neoplastic; Cytarabine; Decitabine; Female; Gene Expression Regulation, Neoplastic; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Predictive Value of Tests; Prognosis; Ribosomal Proteins; Risk Factors; Treatment Outcome; Young Adult | 2012 |
Methylation of the p73 gene in patients with myelodysplastic syndromes: correlations with apoptosis and prognosis.
Topics: Adult; Aged; Apoptosis; Azacitidine; Bone Marrow Cells; Cells, Cultured; Cytarabine; Decitabine; DNA Methylation; DNA-Binding Proteins; Female; Humans; Male; Middle Aged; Myelodysplastic-Myeloproliferative Diseases; Nuclear Proteins; Prognosis; Promoter Regions, Genetic; Survival; Tumor Protein p73; Tumor Suppressor Proteins | 2013 |
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; DNA Mutational Analysis; Female; Glutarates; Granulocyte Precursor Cells; Humans; Idarubicin; Isocitrate Dehydrogenase; Leukemia, Myeloid; Male; Middle Aged; Mutation; Prospective Studies; Time Factors | 2012 |
What is better for older patients with acute myeloid leukemia?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Choice Behavior; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Palliative Care; Patient Participation | 2013 |
When azanucleoside treatment can be curative: nonintensive bridging strategy before allografting in older patients with myelodysplastic syndrome/acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Choice Behavior; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Palliative Care; Patient Participation | 2013 |
Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.
Topics: Animals; Azacitidine; Cytarabine; Cytidine; Cytidine Deaminase; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Female; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Male; Mice; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Survival Analysis; Treatment Outcome | 2013 |
Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cell Transformation, Neoplastic; Combined Modality Therapy; Cytarabine; Decitabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Myeloproliferative Disorders; Philadelphia Chromosome; Registries; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Young Adult | 2013 |
Epigenetic action of decitabine (5-aza-2'-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C).
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cell Survival; Cytarabine; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Approval; HL-60 Cells; Humans; Leukemia, Myeloid; Middle Aged; Remission Induction; Survival Analysis; Treatment Outcome; United States; United States Food and Drug Administration | 2013 |
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells.
Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Azacitidine; Cell Line, Tumor; Cell Survival; Clofarabine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Flavonoids; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Myeloid; Piperidines; Purines; RNA Polymerase II; RNA, Neoplasm; Roscovitine; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
[Exudative pericardial effusion and oligoarthritis in a patient newly diagnosed with myelodysplastic syndrome].
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Arthritis; Azacitidine; Cytarabine; Disease Progression; Etoposide; Fatal Outcome; Hepatomegaly; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Serositis | 2014 |
inv(2)(p23q13)/RAN-binding protein 2 (RANBP2)-ALK fusion gene in myeloid leukemia that developed in an elderly woman.
Topics: Aged; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Inversion; Chromosomes, Human, Pair 2; Cytarabine; Daunorubicin; Diagnosis, Differential; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Molecular Chaperones; Nuclear Pore Complex Proteins; Oncogene Proteins, Fusion; Receptor Protein-Tyrosine Kinases; Treatment Outcome | 2014 |
[Cutaneous infiltratiton by chronic myelononocytic leukemia: presentation of three cases].
Topics: Aged; Antineoplastic Agents; Azacitidine; Cytarabine; Fatal Outcome; Humans; Hydroxyurea; Leukemia, Myelomonocytic, Chronic; Leukemic Infiltration; Male; Skin | 2013 |
Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Case-Control Studies; Chemotherapy, Adjuvant; Cladribine; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Recombinant Proteins; Treatment Failure; Young Adult | 2014 |
Cladribine in the treatment of acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cladribine; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Myelodysplastic Syndromes; Recombinant Proteins | 2014 |
Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts--a retrospective single-center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Cytarabine; Drug Administration Schedule; Female; Hemorrhage; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Palliative Care; Pneumonia; Retrospective Studies; Survival Analysis | 2014 |
HLA-partially matched cellular therapy (stem-cell microtransplantation) for acute myeloid leukaemia: description of four cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Graft Survival; Graft vs Leukemia Effect; Histocompatibility; HLA Antigens; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukocyte Transfusion; Male; Middle Aged; Remission Induction; Tissue Donors | 2014 |
Acute basophilic leukemia.
Topics: Aged; Antibiotics, Antineoplastic; Antigens, CD; Antimetabolites, Antineoplastic; Asthenia; Azacitidine; Basophils; Bone Marrow; Cytarabine; Female; Humans; Idarubicin; Leukemia, Basophilic, Acute; Leukemia, Myeloid, Acute | 2014 |
[Clinical efficacy of decitabine combined with modified CAG regimen for relapsed-refractory acute myeloid leukemia with AML1-ETO⁺].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Core Binding Factor Alpha 2 Subunit; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Oncogene Proteins, Fusion; Recurrence; Retrospective Studies; RUNX1 Translocation Partner 1 Protein; Treatment Outcome; Young Adult | 2014 |
[Comparison of clinical efficacy between decitabine combined with CAG regimen and CAG regimen alone in patients with intermediate to high-risk myelodysplastic syndromes].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Disease-Free Survival; Granulocyte Colony-Stimulating Factor; Humans; Myelodysplastic Syndromes; Remission Induction; Treatment Outcome | 2014 |
[The clinical efficacy of the patients of acute myeloid leukemia and myelodysplastic syndromes treated with decitabine alone, combined with half or one couse of CAG regimen].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2014 |
Treatment of elderly patients with acute myeloid leukemia with azacitidine results in fewer hospitalization days and infective complications but similar survival compared with intensive chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Female; Follow-Up Studies; Hospitalization; Humans; Idarubicin; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Expression of microRNA-331 can be used as a predictor for response to therapy and survival in acute myeloid leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Azacitidine; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Young Adult | 2015 |
[Clinical resarch of decitabine combined with modified CAG regimen for treatment of relapsed or refractory acute myeloid leukemia].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Decitabine; Epigenesis, Genetic; Female; fms-Like Tyrosine Kinase 3; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Cytidine Deaminase; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Inactivation, Metabolic; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide | 2015 |
Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML).
Topics: Aged; Alternative Splicing; Anthracyclines; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Chromosomal Proteins, Non-Histone; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Exons; Gene Expression Profiling; HEK293 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Oncogene Proteins; Oncogenes; Poly-ADP-Ribose Binding Proteins; RNA Interference; RNA, Small Interfering; WT1 Proteins | 2016 |
[Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Karyotype; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pancytopenia; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chromosome Aberrations; Cytarabine; Decitabine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Recurrence; Remission Induction; Treatment Outcome | 2016 |
The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients.
Topics: Aclarubicin; Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cytarabine; Decitabine; Disease-Free Survival; Female; Harringtonines; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Young Adult | 2015 |
Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Topics: Abnormal Karyotype; Aclarubicin; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Cytarabine; Decitabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematuria; Humans; Induction Chemotherapy; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2015 |
[Outcomes of refractory or relapsed DNMT3A + cytogenetically normal acute myeloid leukemia patients followed the therapy including decitabine combined with CAG or CAG-like regimen].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Disease-Free Survival; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mutation; Remission Induction; Retrospective Studies | 2015 |
Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Synergisitic and Antagonistic AML Cell Type-specific Responses to 5-Aza-2-deoxycitidine and 1-h-D-Arabinofuranoside.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cell Survival; Cytarabine; Decitabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Time Factors | 2016 |
Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis.
Topics: Adult; Aged; Aged, 80 and over; Antibiotic Prophylaxis; Antimetabolites, Antineoplastic; Azacitidine; Bacterial Infections; Cytarabine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Risk Factors; Virus Diseases | 2016 |
Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone.
Topics: Aclarubicin; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Karyotype; Male; Middle Aged; Mutation; Retrospective Studies | 2017 |
Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Human Leukocyte Antigen-Mismatched Stem Cell Microtransplantation Improved Outcomes in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Histocompatibility; HLA Antigens; Humans; Karyotype; Leukemia, Myeloid, Acute; Middle Aged; Prospective Studies; Remission Induction; Stem Cell Transplantation | 2017 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |
Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
Topics: Aged; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; Female; Humans; Karyotype; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasms, Second Primary; Proportional Hazards Models; Remission Induction; Retrospective Studies; Treatment Outcome | 2017 |
Successful Management of Decitabine prior to Full-Dose Idarubicin and Cytarabine in the Treatment of Refractory/Recurrent Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; Cytarabine; Decitabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Transplantation, Homologous | 2017 |
Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Computational Biology; Cytarabine; Databases, Genetic; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Ontology; Gene Regulatory Networks; Humans; Leukemia, Myeloid, Acute; Molecular Sequence Annotation | 2017 |
With me or against me: Tumor suppressor and drug resistance activities of SAMHD1.
Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Autoimmune Diseases of the Nervous System; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cytarabine; Decitabine; Drug Resistance; Humans; Leukemia, Myeloid; Monomeric GTP-Binding Proteins; Mutation; Nervous System Malformations; SAM Domain and HD Domain-Containing Protein 1; Survival Analysis; Treatment Outcome; Tumor Suppressor Proteins | 2017 |
[Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
Topics: Aclarubicin; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome | 2017 |
Monophosphorylation by deoxycytidine kinase affects apparent cellular uptake of decitabine in HCT116 colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Camptothecin; Colonic Neoplasms; Cytarabine; Decitabine; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Etoposide; Gemcitabine; HCT116 Cells; Humans; Irinotecan; Phosphorylation | 2017 |
[Curative Effect of Decitabine Combined with IAG Regimen for Senile Patients with Myelodysplastic Syndrome (MDS) Transformed Acute Myeloid Leukemia].
Topics: Alzheimer Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Treatment Outcome | 2017 |
Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cladribine; Cytarabine; Decitabine; Drug Administration Schedule; Humans; Leukemia, Myeloid; Middle Aged; Mutation; Remission Induction; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2018 |
[Clinical Efficacy of Decitabine Combined with or without Cytarabine-based Low Dose Regimen for Senile patients with Acute Myeloid Leukemia].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Retrospective Studies; Treatment Outcome | 2018 |
Major response of PNH to an AML chemotherapy protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Cytarabine; Daunorubicin; Hemoglobinuria, Paroxysmal; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction | 2018 |
Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab.
Topics: Antigens, CD20; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fatal Outcome; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Molecular Targeted Therapy; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prednisone; Rituximab; Vincristine | 2018 |
[Clinical Efficacy of Decitabine-Based Chemotherapy Regimens in the Treatment of Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Treatment Outcome | 2018 |
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Cytogenetics; Female; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation | 2018 |
Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Cytarabine; Female; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Survival Rate; Treatment Outcome; Young Adult | 2019 |
Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Azacitidine; Cytarabine; Decitabine; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies | 2018 |
Very rare lineage switch from acute myeloid leukemia to mixed phenotype acute leukemia, B/Myeloid, during chemotherapy with no clonal evolution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged | 2019 |
Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase I as Topic; Cytarabine; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Remission Induction; Sulfonamides; Treatment Outcome | 2019 |
Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged ≥ 60 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate | 2020 |
Efficacy of sodium hypochlorite in the degradation antineoplastic drugs by NMR spectroscopy.
Topics: Antineoplastic Agents; Azacitidine; Carcinogens; Cytarabine; Decontamination; Drug Interactions; Ethanol; Fluorouracil; Humans; Hypochlorous Acid; Irinotecan; Magnetic Resonance Spectroscopy; Occupational Exposure; Preliminary Data; Sodium Chloride; Sodium Hypochlorite; Time Factors | 2020 |
Dose-Reduced Decitabine Might Bring Benefits for Elderly AML Patients with Complex Karyotype: a Case Report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Humans; Karyotype; Leukemia, Myeloid, Acute; Remission Induction; Treatment Outcome | 2020 |
Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Risk Factors; Sulfonamides; Tumor Lysis Syndrome | 2021 |
DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Child; Clinical Trials, Phase III as Topic; Cytarabine; Datasets as Topic; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Epigenetic Repression; Female; Gene Expression Regulation, Leukemic; HEK293 Cells; Humans; Leukemia, Myeloid, Acute; Male; Organic Cation Transport Proteins; Progression-Free Survival; Randomized Controlled Trials as Topic; Symporters; Young Adult | 2021 |
Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Decitabine; Drug Combinations; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Sulfonamides; Young Adult | 2020 |
Challenges in treatment of patients with acute leukemia and COVID-19: a series of 12 patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; COVID-19; Cytarabine; Extracorporeal Membrane Oxygenation; Female; Humans; Leukemia, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; SARS-CoV-2; Treatment Outcome | 2020 |
Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia.
Topics: Animals; Azacitidine; Cytarabine; Leukemia, Myeloid, Acute; Mice; Myelodysplastic Syndromes; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-hck | 2022 |
Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia.
Topics: Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2021 |
Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Humans; Japan; Leukemia, Myeloid, Acute; Retrospective Studies; Treatment Outcome | 2022 |
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia.
Topics: Aged; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Prospective Studies; Quality of Life; Retrospective Studies; Sulfonamides | 2022 |
Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclax.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Hospitalization; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
Utility of therapeutic drug monitoring of venetoclax in acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Cytochrome P-450 CYP3A Inhibitors; Drug Monitoring; Humans; Itraconazole; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Retrospective Studies | 2023 |
[Analysis of the efficacy of azacitidine combined with homoharringtonine and cytarabine in induction and salvage therapy of acute myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Remission Induction; Salvage Therapy; Treatment Outcome | 2022 |
Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials, Phase I as Topic; Cytarabine; Humans; Leukemia, Myeloid, Acute | 2023 |